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Stellingen 
1. 18F-DOPA PET/CT is de eerste keus voor beeldvorming om catecholamine­
producerende tumoren op te sporen. 
2. Endoscopische echografie is de meest gevoelige techniek om een eilandjesceltumor 
in de pancreas te lokaliseren. 
3. Bij patienten die langdurig somatostatine-analoog krijgen moeten regelmatig de 
bloedspiegels van de vetoplosbare vitamines gecontroleerd worden. 
4. Het glucose-verhogende effect van everolimus bij gemetastaseerde insulinomen 
wordt veroorzaakt door een direct anti-tumoreffect en een effect op de perifere 
insulinegevoeligheid. 
5. Patienten met uitgezaaide eilandjesceltumoren kunnen ook cardiale metastasen 
hebben. 
6. Betere behandeling van het gemetastaseerde carcinoid heeft geleid tot een lagere 
incidentie van de carcinoide hartziekte. 
7. Een rookverbod in de openbare ruimte reduceert de incidentie van het acuut 
coronair syndroom in niet-rokers en rokers. 
8. De frequente toepassing van medische beeldvorming leidt voor patienten tot een 
substantiele blootstelling aan straling met als gevolg een verhoogd risico op het 
ontwikkelen van kanker. 
9. Aspectparen van het Russische werkwoord moeten eerder als 2 verschillende 
woorden dan als 2 vormen van 1 woord beschouwd worden. 
10. Overal bereikbaar zijn is gelijk aan altijd gestoord kunnen worden. 
11. Nederlanders zouden beter met Duitsers overweg kunnen als ze niet tegen hen 
hoefden te voetballen. 
12. De echte kunst van het promoveren is het om de meningen van alle 
medeonderzoekers tot een geheel te combineren. 
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Chapter 1 Introduction 
Chapter 1 INTRODUCTION Neuroendocrine tumors are a heterogeneous group of rare tumors, which arise from cells of the (neuro )endocrine system. These cells are located throughout the body and are capable of secreting biologically active amines, peptides and hormones. They can be divided into cell types that form localized glands (for example the adrenal medulla and the paraganglia) and cells that are dispersed throughout the entire body in other organs: the diffuse neuroendocrine system.1 Tumors originating from the chromaffin cells of the adrenal medulla are classified as pheochromocytoma, while tumors of the sympathetic and parasympathetic paraganglia are called paraganglioma.2 Neuroendocrine tumors that arise from the diffuse neuroendocrine system are mainly localized in the intestine, pancreas and lung, although they can originate in other organs as well.3 Intestinal neuroendocrine tumors are most commonly found in the small intestine, followed by the rectum and appendix. Neuroendocrine tumors that arise from the pancreas are called islet cell tumors. The World Health Organisation (WHO) categorizes neuroendocrine tumors based on histological features. 2 The main categories defined by this classification system are well differentiated (neuro )endocrine tumor, well­differentiated neuroendocrine tumors of uncertain behavior, well­differentiated neuroendocrine carcinomas and poorly differentiated neuroendocrine carcinomas. In this thesis the term carcinoid tumor is used to describe the well-differentiated neuroendocrine tumor of the gastrointestinal tract. For tumor localization anatomical imaging, including computer tomography (CT), magnetic resonance imaging (MRI) or endoscopic ultrasound, in combination with nuclear functional imaging is performed, such as somatostatin receptor scintigraphy (SRS) using min-octreotide (for carcinoids and islet cell tumors) or scintigraphy with 1231-labeled meta-
- 8 -
Introduction iodobenzylguanidine (for pheochromocytomas). Positron emission tomography (PET) using 6-[F-18]fluoro-L-dihydroxyphenylalanine (18F­DOPA) or 11C-5-hydroxytryptophan (1 1C-5-HTP) exploit the intrinsic property of neuroendocrine tumors to take up, decarboxylate, and store amine precursors. Surgical excision is the curative treatment option, but it can also be used in a palliative setting to prevent local problems and decrease hormone production. Also in case of metastatic disease median survival for well­differentiated neuroendocrine tumors is relatively long.3 Not only new imaging modalities but also new therapeutic options are currently being developed. New targeted drugs have shown promising results in patients with neuroendocrine tumors.4-7 Aim of this thesis The aim of this thesis is to address the diagnosis and management of patients with neuroendocrine tumors, focusing on carcinoid tumors, islet cell tumors and pheochromocytomas. Outline of this thesis Chapter 2 gives an extensive literature overview of the imaging methods used to visualize neuroendocrine tumors of the pancreas. A search was performed in the PubMed Medline and Embase databases of all English publications on imaging of islet cell tumors between 1995 and December 2009. When more than 5 studies were available for an imaging technique, only studies with more than 10 patients for that imaging technique were considered. Three indications can be distinguished for imaging of these tumors namely 1) tumor localization and staging of a patient with symptomatic pancreatic hormone hypersecretion, 2) a chance finding of a neuroendocrine tumor or its metastases and the subsequent search for a - 9 -
Chapter 1 primary (pancreatic) tumor, and 3) screening in asymptomatic VHL and MENl-mutation carriers. The number of patients in the studies was used as a weight factor in summarizing results for different imaging techniques per imaging indication and results are presented in Forest plots. For the applicability of each imaging technique a level of evidence is assigned, based on the system of the Oxford Centre of Evidence Based Medicine. Currently, no criteria exist to unequivocally predict malignancy of pheochromocytomas. Only the presence of chromaffin tissue at sites, where it is normally absent, establishes a definite diagnosis of malignancy.8 Therefore, adequate staging is essential since the detection of metastases affects treatment. 18F-DOP A PET has shown the potential to improve pheochromocytoma localization in initial small studies.9-11 Chapter 3 describes the study designed to compare the sensitivity of 18F-DOP A PET imaging with the results of morphological imaging using CT and MRI, and functional whole body imaging with 123I-MIBG scintigraphy in patients with proven catecholamine excess. A total of 48 patients were studied. Analysis was performed on a patient and lesion-based level. Results of cytological, histological findings, all imaging tests, follow-up and biochemical data served as a composite reference standard. Metanephrines and 3-methoxytyramine were determined in plasma and urine. In addition, uptake of 18F-DOP A was measured with PET to determine the whole-body metabolic burden and correlated with biochemical tumor markers. Chapter 4 describes the study which was performed to investigate the value of 11C-5-HTP PET to detect cardiac metastases in patients with a metastasized islet cell tumor. Thus far only in one patient a cardiac metastasis from an islet cell tumour has been reported. The frequency of cardiac metastases may be underestimated as MRI, CT and [18F]fluoro-2-deoxy-d-glucose (18F-FDG) PET do have trouble detection these due to their technical properties. A renewed analysis was performed of all 26 patients with metastasized islet cell tumors who underwent an 11C-5-HTP PET scan - 10 -
Introduction earlier. An 11C-5-HTP PET scan was found to be the best method to visualize islet cell tumors. When lesions suspect for cardiac metastases were identified with 11C-5-HTP PET scan, chest-CT scans were reviewed and fused with the 11C-5-HTP PET. 
Chapter 4a addresses the value of 18F-DOP A PET to detect also cardiac metastases in a patient with a metastasized carcinoid. This patient underwent 18F-DOPA PET, SRS, echocardiography, elektrocardiography and cardiac MRI as a part of his oncological work-up. Second primary malignancies occur more frequently in carcinoid patients than in the general population. Given the relative long survival, even in case of metastatic carcinoid disease, a second primary malignancy can deserve full treatment. Distinguishing a second primary malignancy from a carcinoid metastasis is therefore important, and may have therapeutic consequences. The aim of the study described in chapter 5 was to analyze whether differentiation between carcinoid metastases and the second primary malignancy scan be achieved using the difference in uptake between different PET tracers. 18F-DOP A PET, which uses the ability of neuroendocrine tumors to take up and decarboxylate amine precursors, was performed to localize the carcinoid tumor. Staging of the second primary malignancy was performed using 18F-FDG as radiotracer for the glucose metabolism, which is ideal to detect fast-growing tumors, but inadequate to detect the slow-growing carcinoid tumors. We checked the charts of 109 carcinoid patients to identify patients who presented with a new second primary malignancy and in whom differentiation between carcinoid lesions and the second primary malignancy was guided by PET imaging with the two aforementioned tracers. Biochemical tumor markers in plasma or urine are when produced by metastatic carcinoids, used in the diagnosis and follow-up. PET imaging opens ways to analyze whole-body metabolic tumor burden as new quantitative measure of the overall tumor load. 18F-DOPA-tumor uptake 
-11-
Chapter 1 and the levels of secreted biochemical tumor markers are mediated by its endocrine metabolic activity. The aim of the study described in Chapter 6 was to evaluate whether total 18F-DOPA-tumor uptake on PET, defined as the whole-body metabolic tumor burden reflects tumor load per patient, as measured with tumor markers. Data of 76 patients with a carcinoid tumor who underwent 18F-DOPA PET as well as a careful collection of relevant biochemical tumor markers in two previously published 18F-DOP A PET studies of our institute were analyzed. The inclusion criteria for these studies were patients with a strong suspicion of a carcinoid tumor, based on clinical and biochemical findings, and patients with histopathologically proven carcinoid tumor, with a clinical indication for (re)staging. All patients had to have at least one abnormal lesion on conventional imaging. As tumor markers served 24-hour urinary serotonin, urine and plasma 5-hydroxindole acetic acid (SHIAA); catecholamines (nor)epinephrine, dopamine and their metabolites, measured in urine and plasma, and serum chromogranin A. For all tumor lesions mean standardized uptake values (SUVmean) at 40% of the maximal SUV and tumor volume at this SUV mean on 18F-DOP A PET were determined using a computer-generated volume of interest. SUVmean and tumor volume were multiplied to calculate a metabolic burden per lesion. Whole-body metabolic burden was the sum of the metabolic burden of all individual tumor lesions per patient. Whole-body metabolic tumor burden was correlated with the tumor markers. Recently the mTOR inhibitor everolimus administered to four insulinoma patients showed rapid effect on glucose normalization.12 The precise explanation for these findings is however not yet unraveled. In Chapter 7 we describe the analyses which we performed to identify the kinetics of everolimus-effects on control of hypoglycemias and to understand underlying mechanisms. Three patients with metastatic insulinoma received everolimus orally daily. We measured serial serum -12 -
Introduction glucose and plasma insulin and proinsulin levels in three patients with a metastasized symptomatic insulinoma. CT scans were performed before and after 2 and 5 months treatment. 18F-FDG-PET to visualize whole body glucose metabolism were done before and after 2 weeks, 5 weeks and 5 months of treatment. Standardized uptake values of tumor lesions on PET were calculated to quantify tracer uptake. Somatostatin analogues negatively influence fat uptake in the bowel, frequently resulting in steatorrhea. Together with fecal fat loss, potentially fat-soluble vitamins can be lost. The effect of long-term somatostatin analogue treatment on fat-soluble vitamin levels is unknown. In Chapter 8 we investigated the frequency and severity of fat-soluble vitamin deficiencies in 19 acromegaly and 35 carcinoid patients, which were treated with a somatostatin analogue for more than 18 months. In these patients we determined the levels of the fat-soluble vitamins and checked for signs and symptoms of vitamin deficiencies. Possible influencing factors were also recorded. Chapter 9 summarizes our observations and addresses future perspectives. Chapter 10 gives a summary of this thesis in Dutch. - 13 -
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Chapter 2 
ABSTRACT Islet cell tumors of the pancreas are rare neuroendocrine tumors, which can produce hormones in 40% of the cases. They arise sporadically or as part of the hereditary cancer syndromes. The literature on the value of imaging of islet cell tumors presents an array of varying results for different imaging techniques. Currently, technical innovation improves conventional imaging techniques. In addition apart from anatomical imaging, specific molecular imaging, permitted by the neuroendocrine nature of these tumors, increasingly plays a role. To organize the heterogeneous results described for the imaging of these tumors, we distinguished three indications namely 1) imaging of a patient with hormone hypersecretion, 2) a chance finding of a neuroendocrine tumor or its metastases and the subsequent search for a primary (pancreatic) tumor, and 3) screening of asymptomatic mutation carriers. For these indications we searched in Pubmed, Medline and Embase databases for all English publications on imaging of islet cell tumors between 1995 and January 2010 and defined a Level of Evidence (LOE) for the applicability of each technique. Data were analyzed in a Forest plot for each technique separately and are arranged per imaging indication and per islet cell tumor subtype to give a clear overview of the available literature. We show that LOEs are weak (2b at best) for all imaging techniques. Our analyses with Forest plots point towards especially a prominent role for endoscopic ultrasound for all three indications studied. 
- 16 -
Imaging islet cell tumors I. INTRODUCTION Islet cell tumors of the pancreas are rare tumors, occurring in approximately one in 100,000 adults. They originate from the pancreatic islet cell lineage and can secrete one or more hormones or amines.I Up to 60% of these tumors are non-functioning; around 50% present with hepatic metastases at time of diagnosis.2, 3 Tumors are classified as functioning or non-functioning, based on presence of symptoms caused by hormone production. 4 Non-functioning tumors are generally detected in a late stage and present with non-specific symptoms or mass effects due to their (large) size or metastases. Functioning islet cell tumors are characterized according to the biological substance secreted. Insulinomas are typically small and in 90% benign tumors, presenting with hypoglycaemia. Gastrinomas can cause the Zollinger-Ellison syndrome, characterized by high gastric acid output, and are usually small and malignant.I Most gastrinomas arise in the gastrinoma triangle, comprising the head of the pancreas, the superior and descending portion of the duodenum and local lymph nodes.5 Glucagonomas, which can cause diabetes and a characteristic rash, and VIPomas, which can be associated with severe diarrhea, are often large primary tumors and already metastasized at diagnosis.I Other subgroups of functioning islet cell tumors are even rarer, occurring in less than 0.1 per million adults.I, 6 Islet cell tumors can arise sporadically or as part of two hereditary cancer syndromes namely multiple endocrine neoplasia type 1 (MENl) and van Hippel Lindau disease (VHL).7, 8 Patients with an islet cell tumor have a chance of 5-30%, depending on the subtype of islet cell tumor, that an underlying genetic predisposition is present.6 Carriers of a MENl mutation will develop islet cell tumors in 30-80%, those with a VHL gene mutation in 10-20%. - 17 -
Chapter 2 Diagnosing hormone or amine hypersecretion may help to confirm the suspicion of a functioning tumor in a patient with symptoms, but other causes of elevated hormone or amine levels have to be ruled out.1 For non­functioning tumors extensive hormonal testing is usually little helpful. In either case, biochemical measurements do not provide tumor localization and thereby more direct proof of an islet cell tumor. Imaging is essential to localize the primary tumor, to detect metastases and to assess tumor response on treatment. Historically, visualization of pancreatic lesions has been difficult. The literature on the value of imaging of islet cell tumors presents a broad assortment of varying results for different imaging techniques. Interpreting the available imaging results is a challenge. Firstly due to the rarity of the disease most studies are performed in small and/or mixed patient cohorts. Secondly, many imaging techniques exist often without studies in which head to head comparisons were performed. Thirdly, clinically three indications can be distinguished for imaging of these tumors which are often all included in studies leading to confusing conclusions. To organize the heterogenous results described for the imaging of these tumors, we distinguished three indications namely 1) tumor localization and staging of a patient with symptomatic pancreatic hormone hypersecretion, 2) a chance finding of a neuroendocrine tumor or its metastases and the subsequent search for a primary (pancreatic) tumor localization and staging, and 3) screening in asymptomatic VHL and MENl-mutation carriers. In the present review, we give an overview of the performance of the various imaging techniques, their strength and weaknesses in relation to the three imaging indications described above and highlight standard as well as the place of newer techniques. - 18 -
Imaging islet cell tumors II. METHODS We performed a non-systematic review of all publications between 1995 and January 2010 on imaging of pancreatic islet cell tumors. Articles were searched in the PubMed, Medline and Embase databases using a variety of search terms, including: imaging, visualization, localization, pancreatic neuroendocrine tumor or neoplasm, islet cell tumor, insulinoma, gastrinoma, glucagonoma, VIPoma and somatostatinoma. Only articles in the English language were included. Results from reviews without original data were excluded. The reference lists of all articles were checked for unknown publications. When more than 5 studies were available for an imaging technique, only studies with more than 10 patients for that technique were considered. When fewer studies were available, smaller studies and relevant case reports were also included. The full texts of the articles were reviewed, and whenever possible, we extracted and tabulated sensitivity and specificity values for the three imaging indications: 1) imaging of a patient with hormone hypersecretion, 2) a chance finding of a neuroendocrine tumor or its metastases and the subsequent search for a primary (pancreatic) tumor localization and staging, and 3) screening of mutation carriers of MENl and VHL. The number of patients in the studies was used as a weight factor in summarizing results for different imaging techniques and is represented by a square in the Forest plot analysis. For Forest plot calculations for CT scanning were performed for studies in which a multidector CT (MDCT) was used or, given the technical improvements in CT scanning, studies published in the last 7 years. For the applicability of each imaging technique a Level of Evidence (LOE) was assigned, based on the system of the Oxford Centre of Evidence Based Medicine.9 Level la evidence is considered definite; level 5 evidence is considered weak. - 19 -
Chapter 2 
RESULTS III. Anatomical imaging A. Transabdominal and endoscopic ultrasound 
Transabdominal ultrasound Transabdominal ultrasound was one of the first imaging techniques available for the imaging of pancreatic neuroendocrine tumors. It is safe, non-invasive, relatively inexpensive and widely available. For tumor localization in a symptomatic patient transabdominal ultrasound can localize pancreatic insulinomas in 10 -40% of the cases (range 9-79%).10-21 Performance improves with increasing lesion size. In 120 patients with hyperinsulinism surgically confirmed tumors larger than 2 cm were detected with transabdominal ultrasound in 56%, but only 18% of those smaller than 1 cm.10 Detection is also limited by interference of other intra­abdominal organs (for example bowel gas) and fat in obese patients.11 Combining ultrasound with other imaging techniques improves detection rates; ultrasound plus magnetic resonance imaging (MRI) rendered a sensitivity of 97% in a study of 28 insulinoma patients with lesions of 0 .8-4.3 cm at surgery.11 Overall ultrasound has a LOE 2b for the detection of tumors in patients with hyperinsulinism. Pancreatic gastrinomas are detected by transabdominal ultrasound in 71 % of 14 patients (LOE 2b).20 No studies have looked at the value of transabdominal ultrasound for tumor localization in patients with a chance tumor finding, or for the screening of MENl or VHL-patients. One guideline still advocates transabdominal ultrasound as first imaging technique to localize non-functioning suspected islet cell tumors22, despite the poor sensitivity described above. New developments, such as Doppler sonography23 or the use of contrast agents24, 25, can improve the performance of transabdominal ultrasound. These developments have not yet been investigated for the localization of pancreatic islet cell tumors. It - 20 -
Imaging islet cell tumors remains to be proven whether addition of these techniques can result in a good sensitivity for transabdominal ultrasound. 
Endoscopic ultrasound Endoscopic ultrasound (EUS) has evolved as a relevant technique to localize islet cell tumors.26 Elastography, next to Doppler, may help distinguish tumors from their surrounding tissues because of their specific consistency27, but has not yet been used in any of the current studies. An advantage of EUS is that it permits direct cytology to be obtained of the visualized lesion by fine needle aspiration (FNA). The yield of FNA may be lower for neuroendocrine tumors than for adenocarcinomas of the pancreas. In a study comparing the feasibility and value of FNA in solid pancreatic masses, the accuracy of FNA was 47% in neuroendocrine tumors (n = 15) and 81 % for pancreatic adenocarcinoma (n = 59). This was possibly due to the vascular nature of neuroendocrine tumors, which resulted in purely hemorrhagic samples with few cells in 47%, making analysis impossible28 and due to their low malignancy grade. When during EUS a FNA was performed with on-site assessment of the adequacy of the specimen a sensitivity and accuracy of both 83% was obtained in a retrospective study in 30 patients with suspected islet cell tumors.29 Only one minor complication (abdominal pain) was reported. Based on their findings, these investigators advise that different strategies should be attempted to optimize the samples different strategies, for example, on-site assessment of the specimen. 29, 30 For tumor localization in symptomatic patients the studies as illustrated in the Forest plot analyses show high sensitivities for EUS (Figure 1). The sensitivities are similar for all islet cell tumor subtypes. Most studies were small, with a median of 29 patients. Small tumors appear as uniformly hypoechoic masses, with distinct margins, but larger and malignant tumors can be inhomogenous, hyperechoic (Figure 2), and can have irregular margins.12, 21 , 31, 32 - 21 -
Chapter 2 
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80 1 00 Figure 1. Results of endoscopic ultrasound presented in a Forest plot analysis. On the left side of this plot the reference of the study is mentioned, on the right side sensitivities from literature data are provided with their calculated confidence intervals and number of patients. Results are clustered per imaging indication. Within the different groups studies are clustered per tumor subtype and according to year of publishing. 95% CI: 95% Confidence Interval 
A B Figure 2. Patient with a small, 0.6 x 0.9 cm, metastasized glucagonoma, presenting with diabetes mellitus, icterus and a rash. A) Endoscopic ultrasound, showing the pancreatic tumor (arrow). On the left adjacent to the tumor the splenic artery (s.a.) and the hepatocaval confluence (c) are visible. B) The lesion is not visualized by computer tomography. 
- 22 -
Imaging islet cell tumors False-positive EUS findings in symptomatic patients can be caused by peripancreatic lymph nodes, imposing as tumoral nodes.32-34 Reported false-negatives usually relate to very small or iso- or hyperechoic insulinomas.35 The influence of size on the detection rates of insulinomas was confirmed in another study.36 Two surgically proven insulinomas not detected by EUS had a mean diameter of 0.75 cm, while the smallest lesion that was detected by EUS measured 0.8 cm. Insulinomas in the pancreatic tail are more difficult to visualize than tumors in the pancreatic head (sensitivity 37-100% versus 83-100%).32, 34 This likely relates to the variable distance of the endoscope, located in the gastric lumen, from the pancreatic tail due to the variable amounts of mesenteric fat. For insulinomas a negative EUS examination does not exclude a pancreatic tumor, given the negative predictive value of 43% found in a study with 36 patients.37 Combining the results of EUS with MDCT, which permits acquisition of thinner slices, improved sensitivity to 100% in 32 patients with insulinomas measuring 0.9-9 cm at surgery.31 The LOE for the performance of EUS to detect tumor in insulinoma patients is only 2b. None of the EUS studies allow for a separate evaluation of the EUS performance for only pancreatic gastrinomas. EUS with FNA on-site assessment of the adequacy of the specimen obtained a sensitivity of 90% and an accuracy of 90% in 10 patients suspected of a functional islet cell tumor.30 Also none of the EUS studies provide a separate evaluation of the EUS performance in patients with a chance finding of neuroendocrine tumor. Three studies report combined results for patients with symptoms or a chance finding of neuroendocrine tumor, which are in the same range as for symptomatic patients alone (Figure 1).29, 37, 38 Median size of these studies is 24 patients. This study also showed that EUS may miss small tumors, as multiple tumors, although not precisely indicated, smaller than 0.2 cm were missed by EUS.37 There is only a LOE 3b for the performance of EUS for tumor detection in patients with a chance finding of neuroendocrine tumor. - 23 -
Chapter 2 For the screening of MENl-carriers EUS performs well, identifying almost all tumors in one small study of 13 individuals (Figure 1). In 12 other patients EUS detected lesions in all patients, while CT and somatostatin receptors scintigraphy (SRS) could demonstrate them in only 1 and 2 patients, respectively.39 EUS was the most sensitive technique, especially for the detection of lesions overall smaller than 1 cm. In most patients multiple small non-functioning tumors were found during surgery, some of which were missed even by EUS. No studies are performed as screening in VHL patients. For the screening of MENl­mutation carriers with EUS there is a LOE 2b. 
B. Computer tomography CT is the most widely used imaging technique for the localization of islet cell tumors. As a consequence of their hypervascular nature, islet cell tumors typically are enhancing masses on contrast enhanced CT images during the arterial phase, in which the tumors are usually best visualized (Figure 3A).40, 41 However, 4-8% of tumors are only visible during the portal-venous phase.41, 42 Therefore, arterial phase and portal-venous phases are complementary, and both are recommended for the detection of islet cell tumors (LOE 2b). For the tumor localization in a symptomatic patient Forest plot analyses show that the performance of CT varies widely between different studies (Figure 4). Patient numbers in these studies are low (median 30 patients) . MDCT allows optimized scan protocols and improved sensitivity, from 29% for non-helical CT to 94 % for MDCT with thin slices in insulinomas.31 Most studies with conventional CT are in the lower range. This is certainly true for patients suspect for an insulinoma or in patients with varying islet cell tumor subtypes. - 24 -
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A B 
C D 
E Figure 3. Illustration of yield of different imaging techniques in a patient with a metastasized non-functioning islet cell tumor, 2 x 2.7 cm. A lesion in the pancreas and liver metastases are visualized on all imaging techniques. A. Computer tomography shows precise anatomical location of the pancreatic lesion and of multiple liver metastases. B. Somatostatin receptor scintigraphy shows tracer uptake in pancreas and liver lesions. C. 11C-HTP PET demonstrates uptake in the pancreas and multiple liver metastases. D. 18F-DOP A PET shows lesions in the pancreas and liver, more lesions were observed with 11C-HTP PET. E. A fusion image of 1 1C-HTP PET and CT demonstrates multiple liver metastases. 
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80 1 00 Figure 4. Results of computer tomography in publications published between 2003 and January 2010 and all MDCT studies presented in a Forest plot analysis. On the left side of this plot the reference of the study is mentioned, on the right side sensitivities from literature data are provided with their calculated confidence intervals and number of patients. Results are clustered per imaging indication. Within the different groups studies are clustered per tumor subtype and according to year of publishing. 95% CI: 95% Confidence Interval Potential false-negatives include insulinomas adjacent to vessels, pedunculated morphology, non-enhancing lesions and insulinomas immediately adjacent to the small bowel.41 Detection rate of insulinomas is also related to tumor size. In a study published in 1998 in 120 patients with hyperinsulinism (105 insulinomas) CT detected 20% of surgically proven tumors smaller than 1 cm, and 40% of tumors larger than 2 cm.10 In another study published in 1999 in 66 patients with hyperinsulinism the detection rate of CT increased from 21 % to 40% to 100% as tumor size increased from 1 cm to 3 cm and 6 cm.14 The level of evidence for CT and MDCT for tumor localization in patients with hyperinsulinism is LOE 2b. Two studies published in 1995 and 1998 (12 and 14 patients respectively) provide detailed information about the value of CT for the detection of 
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Imaging islet cell tumors pancreatic gastrinomas, which lies in the same range as for other islet cell tumor subtypes (60 and 93% respectively).20, 43 The LOE for patients with gastrin hypersecretion is 2b. None of the CT studies allows for a separate evaluation of the CT performance in patients with a chance finding of neuroendocrine tumor. Three studies include both patients with symptoms and those with a chance finding of neuroendocrine tumor (median 23 patients). MDCT shows an excellent sensitivity of 84% in varying subtypes of islet cell tumors.38 For conventional CT the detection rates are low in these patients.29, 44 False-positives were due to inflammatory non-neoplastic masses or aberrant pancreatic tissue.38 There is a LOE2b for the performance of CT for tumor detection in patients with a chance finding of neuroendocrine tumor. For the screening of islet cell tumors in MENl-patients with CT misses a substantial number of lesions, as it could only identify lesions in 1 of 12 patients, that had demonstrated lesions on EUS.39 No studies are available in VHL patients. There is a LOE 2b for the screening of MENl­mutation carriers with CT. C. Magnetic resonance imaging The performance of MRI has greatly improved in recent years as shorter acquisition times resulted in less motion artefacts and higher signal­to-noise ratios. MRI for the detection of islet cell tumors should be performed with a 1.5 Tesla gradient system or higher, using a phased-array torso coil to improve the signal-to-noise ratio.45 For tumor localization in a symptomatic patient Forest plot analyses show that for all tumor subtypes MRI has sensitivities in the lower ranges (Figure 5). Although the difference between studies is wide, it is not as wide as for CT. Like for the other imaging techniques, studies are small (median number 21 patients). 
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80 1 00 Figure 5. Results of magnetic resonance imaging presented in a Forest plot 
analysis. On the left side of this plot the reference of the study is mentioned, on the 
right side sensitivities from literature data are provided with their calculated 
confidence intervals and number of patients. Results are clustered per imaging 
indication. Within the different groups studies are clustered per tumor subtype 
and according to year of publishing. 95% CI: 95% Confidence Interval In two studies (28 and 31 patients) in insulinomas the lesions located in the pancreatic head were easiest to detect, probably because the head is less affected by motion artefacts than the remaining pancreas.11, 46 Other technical limitations include imaging in obese patients or those with irregular breathing.47 MRI performs better with increasing lesion size.11, 14 In 66 insulinoma patients the detection rate of MRI increased from O to 50 to 100% as lesion size increased from 1 to 2 to 3 cm.14 However, a sensitivity of 85% was found in 20 patients with a functional islet cell tumor smaller than 2 cm. These lesions were confirmed at subsequent surgery (18 insulinomas, 2 gastrinomas).47 No studies in gastrinomas could be analyzed in the Forest plot, since detailed information about the performance of MRI to detect pancreatic gastrinomas is lacking. In prospective studies the detection rates of MRI for tumor detection in symptomatic patients or staging in patients with evidence of a tumor or metastases equal those of CT (LOE 2b).11, 42 - 28 -
Imaging islet cell tumors No studies are performed in patients with a chance finding of neuroendocrine tumor alone. Only one study includes both patients with a chance tumor finding and symptomatic patients. This small study including 16 patients found a low detection rate (LOE 2b ). Also no studies have looked at the value of MRI for the screening of MENl or VHL-patients. IV. Molecular imaging Functional molecular imaging is based on cellular properties, such as the presence of somatostatin receptors or the activity of metabolic pathways. Figure 6 shows a schematic depiction of the properties of islet cell tumors that are used to image these tumors. In case of somatostatin receptor imaging the tracer attaches itself to the somatostatin receptor on the cell membrane and this complex is subsequently internalized. The most widely available somatostatin receptor tracer is 1 1 1In-DTPA-D-Phe­octreotide, which targets the somatostatin receptor subtype 2. The same type of mechanism is used for glucagon-like peptide 1 (GLP-1) imaging where the tracer 111In-DOTA-exendin-4 binds the GLP-1 receptor and is then internalized. This is distinct from the several metabolic tracers to visualize neuroendocrine tumors. These metabolic tracers are transported into the cell via cell membrane bound transporters and are then intracellularly metabolized. [18F]fluoro-2-deoxy-d-glucose (18F-FDG) is transported into the cell by the glucose transporter, metabolized and trapped in the cytoplasm. Two other metabolic tracers 11C-5-hydroxytryptophan (11C-5-HTP) and [18F]fluoro-dihydroxyphenylalanin 
(18F-DOP A) are transported into the cell by the large amino acid transporter (LAT), decarboxylated by aromatic-L-amino acid decarboxylase (AADC) to 











transporter Figure 6. Schematic depiction of the different metabolic pathways by which 
neuroendocrine tumors can be visualized using nuclear medicine imaging 
techniques. This can be receptor based techniques and techniques which use the 
metabolic properties of these tumors. 11C-5-HTTP: 11C-5-hydroxytryptophan, 18F­
DOPA: 18F-fluoro-dihydroxyphenylalanin, 18F-FDG: 18F-fluoro-2-deoxy-d-glucose, 
18F-FDG-6-P: 18F-fluoro-2-deoxy-d-glucose-6-phosphate, GLP-1: glucagon-like 
peptide 1, LAT: large amino acid transporter, VMAT: vesicular monoamine 
transporter We will first describe somatostatin receptor imaging, both with the conventional tracer 111In-DTPA-D-Phe-octreotide and newer developments in both single photon emission tomography (SPECT) and positron emission tomography (PET tracers). Thereafter we will cover the various metabolic tracers visualized with PET. A. Single photon emission tomography 
Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe-octreotide Functional nuclear medicine imaging with SRS is based on the fact that 70-100% of islet cell tumors express the human somatostatin - 30 -
Imaging islet cell tumors receptors.48, 49 Most experience is available with 111In-DTPA-D-Phe­octreotide. This gamma camera tracer specifically targets the somatostatin receptor subtype 2 and, to a lesser extent, subtype 550, 51 and is preferably used with SPECT. SRS has the advantage that it can almost ascertain the neuroendocrine nature of suspected lesions found on other imaging techniques (Figure 3B). For tumor localization in a symptomatic patient Forest plot analyses show that the performance of SRS in insulinomas in 2 small studies (14 and 13 patients respectively) is highly variable (Figure 7). The main factors that determine the ability of SRS to detect a pancreatic lesion are its size, the receptor density of the lesion (especially subtype 2) and the target-to-background ratio. In insulinomas, the subtypes of somatostatin receptors, which are necessary for octreotide binding and thus visualization with SRS, are absent in 28% of cases, negatively influencing detection rates 
(LOE 2b ) .49, 51-53 
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Figure 7. Results of somatostatin receptor scintigraphy presented in a Forest plot analysis. On the left side of this plot the reference of the study is mentioned, on the right side sensitivities from literature data are provided with their calculated confidence intervals and number of patients. Results are clustered per imaging indication. Within the different groups studies are clustered per tumor subtype and according to year of publishing. 95% Cl: 95% Confidence Interval - 31 -
Chapter 2 No study allows for separate analysis of patients with a chance finding of neuroendocrine tumors, as all include symptomatic patients as well. One such study is available which evaluated SRS in pancreatic gastrinomas. In this study of 12 patients a perfect performance of SRS is found (LOE 2b) (Figure 7).43 In groups with varying subtypes of islet cell tumors the Forest plot shows varying sensitivities, mainly in the mid to high ranges (Figure 7). Patient numbers in the studies are low (median 19 patients). Results of SRS modified treatment in 56% of 38 patients with suspected islet cell tumors.54 Fusion of CT and SRS images improved detection rates in 23 patients with varying subtypes of islet cell tumors.44 Routine co-registration of SRS with CT, which is becoming more common with the introduction of cameras equipped with a CT scanner (SPECT/CT), is therefore likely to result in a better interpretation of the findings in islet cell tumors and consequently in higher detection rates (LOE 2b ). When used for the screening of MEN-1 patients, SRS could only detect 2 out of 12 asymptomatic patients.39 One study in VHL-patients included 27 patients with islet cell tumors, which were detected during screening, and SRS was positive in 16 of these patients.55 SRS has a LOE 2b for the screening of mutation carriers. 
Newer somatostatin receptor tracers Newer somatostatin receptor tracers for gamma cameras and PET are currently being tested in mixed populations of patients with different neuroendocrine tumors, including islet cell tumors. Studies that investigate these tracers have included both symptomatic patients and patients with a chance tumor finding. As these studies do not allow a separate evaluation of only the islet cell tumor patients, no LOE has been assigned to these studies. Additionally no studies have yet looked at the value of these tracers in mutation-carriers. The two SPECT tracers 99mTc-6-hydrazinopyridine-3-carbolic acid­Tyr3-octreotide (99mTc TOC) and 99mTc-6-hydrazinopyridine-3-carbolic acid-- 32 -
Imaging islet cell tumors Tyr3-Th8-octreotide (99mTc TATE) showed concordance in 12 patients with neuroendocrine tumors (5 islet cell tumors), with 99mTc TATE performing slightly better than 99mTc TOC.56 These two tracers target somatostatin receptor subtypes 2 and 5, and show a higher tumor-to-background ratio and higher tumor uptake than 111In-DTPA-D-Phe-octreotide.57-59 
Glucagon-like peptide 1 scintigraphy GLP-1-receptor scintigraphy uses the SPECT tracer 111In-DOTA­exendin-4, a GLP-1 receptor agonist, to target the GLP-1 receptor. Its rationale is based on the fact that virtually all insulinomas expresss GLP-1 receptors.60 GLP-1-receptor scintigraphy may offer new perspectives for these tumors, which are generally difficult to detect with imaging techniques used sofar. In 8 patients with hyperglycemia it has been used to localize an insulinoma which resulted in a LOE of 4.61, 62 B. Positron emission tomography For PET imaging of neuroendocrine tumors a number of tracers, including somatostatin receptor tracers, are available. In comparison to gamma cameras, PET cameras have a better spatial resolution, and can therefore detect smaller tumors, resulting in better sensitivities.63, 64 The most commonly used tracer in oncology is 18F-FDG, which visualizes tumor glucose uptake. More recently, two other metabolic tracers, based on the intrinsic property of neuroendocrine tumors to take up, decarboxylate, and store amine precursors have been developed (Figure 6). 
Somatostatin receptor imaging with PET Somatostatin receptor tracers are also being developed for PET scanners. 68Ga-DOTA-Tyr3-octreotide (68Ga-DOTA-TOC) PET was superior to SRS and CT in 84 patients with different neuroendocrine tumors, including 25 islet cell tumors, who underwent these tests for initial - 33 -
Chapter 2 detection, staging or follow-up. 68Ga-DOTA-TOC detected 23 of the pancreatic lesions, compared to 21 by SRS and 19 by CT.65 68Ga-DOTA­Nal3-octreotide (68Ga-DOTA-NOC) has the advantage that, in addition to targeting receptor subtypes 2 and 5, it also has a good affinity for the somatostastin receptor subtype 3. This may increase detection rate, since it will also visualize tumors lacking expression of receptor subtypes 2 and 5.57 It showed more positive scans and lesions than 18F-DOP A PET in 13 patients with neuroendocrine tumors (8 islet cell tumors) investigated for initial detection and staging.66 
18F-FDG PET Casuistic evidence reports the value of 18F-FDG PET for islet cell tumor detection.67 One small study in 12 patients with varying subtypes of islet cell tumors has been performed, without clear specification of the indication. In this study only 53% of the tumors could be detected (LOE 2b).68 For example, only 2 out of 5 insulinomas imaged with 18F-FDG PET could be visualized by this technique.68, 69 Tumors with a low glucose metabolism (such as well-differentiated neuroendocrine tumors) often show faint 18F-FDG-uptake and are poorly visualised by PET, while more aggressive less-differentiated tumors (as demonstrated by a high Ki-67 expression) show better 18F-FDG-uptake.70-72 
18F-FDG PET has not been performed for the screening of mutation­carriers. Based on to above data does also does not seem to be of interest. 11C-5-HTP PET PET using the serotonin precursor 11C-5-HTP, another metabolic tracer, is compared to 18F-FDG more specific for neuroendocrine tumors and showed promising results for the imaging of islet cell tumors (Figure 3C). PET scanning with 11C-5-HTP and the catecholamine precursor [11C] dihydroxyphenylalanin (11C-DOP A) were compared in 22 patients with - 34 -
Imaging islet cell tumors clinically and biochemically verified islet cell tumors (5 gastrinoma, 4 glucagonoma, 4 insulinoma, 1 VIPoma, 5 non-functioning). Both tracers showed the same number of lesions, but 11C-5-HTP had higher tracer uptake per lesion (LOE 2b).73 One study is performed that includes patients with a chance finding of neuroendocrine tumors as well as patients that were imaged due to symptoms. In this study in 23 patients with different islet cell tumor subtypes referred for initial tumor detection or follow-up 11C-5-HTP PET reached a sensitivity of 67%.44 Combining 11C-5-HTP PET with CT improved the sensitivity to 96%. The superior performance of 11C-5-HTP PET compared to CT and SRS was confirmed in another study that included 10 patients with islet cell tumors (4 gastrinoma, 1 insulinoma, 5 non-functioning).74 In 25 MEN-1 patients with positive biochemistry or positive CT/transabdominal ultrasound, 11C-5-HTP PET could only identify tumors in 38%.75 11C-5-HTP PET has a LOE 2b to detect an islet cell tumor in these groups with mixed imaging indications. Currently we are evaluating the value of 11C-5-HTP PET for the screening of mutation-carriers (Dutch trial register number: NTR1668). 
18F-DOPA PET The 18F-labeled variant of the catecholamine precursor DOPA (18F­DOP A) is also used as a metabolic PET tracer specific for neuroendocrine tumors (Figure 3D). 
18F-DOP A PET has shown varying results in patients with hyperglycemia. It localized the pancreatic lesion in 9 out of 10 patients with hyperinsulinemia (final histopathological diagnosis was n = 8 insulinomas, n = 2 nesidioblastosis)76, but detected only 1 out of 6 patients in another study.77 Co-administration of the aromatic-L-amino-acid decarboxylase (AADC) inhibitor carbidopa before 18F-DOP A PET has been shown to result in higher tracer availability for tumor uptake, due to inhibition of renal decarboxylation and subsequent clearance of the decarboxylated tracers in - 35 -
Chapter 2 carcinoid tumors and pheochromocytoma.78-81 In case of intrinsically absent tumor AADC-activity, tumor visualization might be affected negatively by pre-treatment with carbidopa.82 Carbidopa masked the uptake of 18F-DOPA in 2 out of 3 patients with hyperinsulinism and in one out of two patients with insulinoma.83, 84 Therefore, the exact place of carbidopa coadministration with PET for islet cell tumors deserves further investigation. 18F-DOP A PET has a LOE 2b for the detection of insulinomas. One study is performed that included patients with a chance finding of neuroendocrine tumors, but it also includes patients that were imaged due to symptoms. 18F-DOPA PET and 11C-5-HTP PET were directly compared in 23 patients referred for initial detection or follow-up, in which 
18F-DOPA PET achieved a sensitivity of 41 %, making it inferior to 11C-5-HTP PET (67%) (LOE 2b).44 No studies have looked at the value of 1 8F-DOPA PET for the screening of mutation-carriers. V. DISCUSSION This systematic review shows that EUS is the most sensitive imaging technique for all three imaging indications of islet cell tumors, but evidence for the application of all imaging techniques is weak. There is a considerable difference between the reported studies with regards to which subtypes of islet cell tumors were included and what the indication for imaging was. There for the results of these studies vary widely in sensitivities. Due to the rarity of the disease, most studies comprised only limited patient numbers, frequently missing a head-to-head comparison. These factors make clear interpretation of the data difficult. Existing guidelines for the localization of the primary tumor and staging of islet cell tumors do not distinguish between symptomatic patients and patients with a chance finding of a neuroendocrine tumor. 
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Imaging islet cell tumors Guidelines from the European Neuroendocrine Tumor Society recommend EUS followed by CT and SRS for imaging of gastrinoma, while for insulinoma CT, MRI and EUS are considered the most useful techniques, without one of those being clearly recommended above the other two.85, 86 For other rare functioning islet cell tumors a combination of CT and SRS is recommended, while for non-functioning tumors a combination of transabdominal ultrasound with CT or MRI and SRS is advocated.22, 87 The NCCN recommends CT or MRI for the localization of the primary tumor and staging for all subtypes of islet cell tumors, and SRS 'as appropriate' .88 Our analyses with Forest plots point towards especially a prominent role for EUS. EUS has the best overall sensitivity to localize tumors in patients presenting with hormone hypersecretion. It shows also the best performance in patients with a chance finding of a neuroendocrine tumor. PET with 11C-5-HTP or 18F-DOPA (likely without carbidopa pre-treatment) has also a good sensitivity, but availability of these techniques is currently still limited while CT, MRI or SRS have only moderate detection rates. Although adding CT to EUS or PET does improve detection rates. Available information about the subtype of islet cell tumor should also be used to guide the choice of imaging technique, since for example SRS is of little value in patients with insulinoma. For the screening of MENl international guidelines propose to use SRS and CT or MRI every 3 years. For VHL a yearly CT scan is advised, while SRS is not routinely recommended.7, 8 Tumors in genetically predisposed individuals are usually multiple and small; therefore techniques with a high spatial resolution are required. A careful algorithm with implementation of new insights seems attractive, since repeated CT or SRS can result in a high cumulative radiation exposure.89, 90 Radiation is a carcinogenic risk factor, which is especially undesirable for the individuals with an inherited predisposition for cancer. In this light, EUS is the best screening tool. Studies comparing CT, SRS, and EUS in MENl (14-22 patients) showed that EUS is the most sensitive technique, while the other - 37 -
Chapter 2 techniques detect only a small fraction of the patients.39, 75, 91 This is especially true for the detection of lesions smaller than 1 cm in size. Therefore EUS deserves a prominent role in the screening of these individuals. No such studies are performed in VHL, but as in these patients the tumors are also small and multiple, EUS is probably also superior in VHL-patients. In VHL EUS-FNA offers the additional advantage that cytology can be obtained to distinguish between a cystadenoma, which are frequently seen in VHL-patients, and a solid islet cell tumor. Lastly, EUS carries no radiation exposure and is therefore safe to use in these patients. Understanding biological and metabolic characteristics of islet cell tumors may help us understand why some tumors can be visualized with certain functional imaging techniques and why others cannot. Knowledge about tumor pathophysiology will provide new insights for the development of better tracers. In this light, the performance of 68Ga-DOTA­labeled somatostatin analogues with PET scanning in patients with islet cell tumors deserves further investigation. It deserves also testing as screenings strategy in patients with hereditary tumors. This imaging technique has the potential to replace the SRS since its tracer has better receptor affinity than 
1 11In-DTPA-D-Phe-octreotide and PET has a better spatial resolution than SPECT. This may be a particular advantage for the imaging of insulinomas not expressing somatostatin receptor subtype 2. The data available from clinical trials that fitted our inclusion criteria still have limitations. No separate sensitivities could be calculated for patients presenting with a chance finding of a neuroendocrine tumor or metastases as they were always analyzed in combination with symptomatic patients. Only one study provided separate sensitivity values for the detection of pancreatic gastrinomas. LOE was the same for all imaging techniques (2b ), except for EUS to image patients with a chance tumor finding (LOE 3b). Therefore the LOEs could not be used to distinguish the best imaging technique. Consequently, the sensitivity value has to be used - 38 -
Imaging islet cell tumors to choose the best imaging technique. To determine the best imaging algorithm there is a great need of adequately sized prospective studies. VI. CONCLUSION Recent years have shown a fast evolution in pre-operative imaging techniques for islet cell tumors. With growing knowledge about these tumors we should now strive to develop new imaging algorithms to choose the right set of procedures in these patients. Imaging can be tailored depending on imaging indication (tumor detection in patients suspected of having an islet cell tumor or screening of mutation carriers) and tumor subtype. The insights gained in this review may serve as a starting-point to investigate the optimal imaging algorithm for (subtypes of) islet cell tumors. 
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Chapter 3 ABSTRACT Context Catecholamine excess is rare, but symptoms may be life-threatening. Objective To investigate the sensitivity of 6-[F-18]fluoro-L-dihydroxyphenylalanine positron emission tomography (18F-DOPA PET), compared to 123l­metaiodobenzylguanidine (1231-MIBG) scintigraphy and CT/MRI for tumor localization in patients with catecholamine excess. Design and Setting All consecutive patients with catecholamine excess visiting the UMCG, Groningen, between March 2003 and January 2008 were eligible. Patients 48 patients were included. The final diagnosis was pheochromocytoma in 40, adrenal hyperplasia in 2, paraganglioma in 2, ganglioneuroma in 1, unknown in 3. Main Outcome Measures Sensitivities and discordancy between 18F-DOP A PET, 1231-MIBG and CT or MRI, were analyzed for individual patients and lesions. Metanephrines and 3-methoxytyramine in plasma and urine, uptake of 18F-DOP A with PET were measured to determine the whole-body metabolic burden and 
- 52 -
18F-DOP A PET for localizing tumors causing catecholamine excess correlated with biochemical tumor activity. Gold standard was a composite reference standard. 
Results 
18F-DOPA PET showed lesions in 43 patients, 123I-MIBG in 31 and CT/MRI in 32. Patient-based sensitivity for 18F-DOPA PET, 123I-MIBG and CT/MRI was 90, 65 and 67% (P<.01 for 18F-DOPA PET vs. both 123I-MIBG and CT/MRI, P=l.0 123I-MIBG vs. CT/MRI). Lesion-based sensitivities were 73, 48 and 44% (P<.001 for 18F-DOPA PET vs. both 123I-MIBG and CT/MRI, P=.51 123I-MIBG vs. CT/MRI). The combination of 18F-DOPA PET with CT/MRI was superior to 123I-MIBG with CT/MRI (93 vs. 76%, P<.001). Whole-body metabolic burden measured with 18F-DOP A PET correlated with plasma normetanephrine (r=0.82), and urinary normetanephrine (r=0.84), and metanephrine (r=0.57). 
Conclusion To localize tumors causing catecholamine excess 18F-DOP A PET is superior to 123I-MIBG scintigraphy and CT/MRI. - 53 -
Chapter 3 INTRODUCTION Catecholamine excess caused by catecholamine-producing tumors is rare, but clinically important since its symptoms may be life-threatening. Patients can often be cured by surgical removal of the tumor. The most frequent catecholamine-producing tumors are pheochromocytomas, which arise from chromaffin cells of the adrenal medulla (80 - 85%) or extra­adrenal paraganglia (15 - 20%).1 However, also other tumors such as ganglioneuromas can produce the clinical symptoms of catecholamine excess. Catecholamine excess is detected by measuring catecholamines and their metabolites in plasma or 24-h urine samples. Imaging techniques are used to localize the primary tumor and to search for metastases. In case of pheochromocytomas most tumors are benign but 10-20% are malignant.1,2 Ruling out metastatic disease before initial surgery is important, because the presence of metastases affects treatment. Computer tomography (CT) and magnetic resonance imaging (MRI) demonstrate good sensitivities in detecting adrenal pheochromocytoma, but exhibit lower sensitivities for extra-adrenal or metastatic disease.1, 3 Functional imaging methods allow further characterization of detected lesions and provide whole-body images. The standard functional imaging technique for catecholamine-producing tumors is scintigraphy with 12311311-labeled meta-iodobenzylguanidine (MIBG), which combines a high sensitivity and high specificity.1, 4, 5 However, sensitivity is lower for malignant pheochromocytoma, and small pheochromocytomas may be missed because of limited spatial resolution of single photon emission computed tomography (SPECT) with 1231131I-MIBG.6, 7 Positron emission tomograpy (PET) imaging with a variety of different tracers has shown that 6-[F-18]fluorodeoxyglucose (FDG) has a high sensitivity in a subset of patients with metastatic disease and underlying succinate dehydrogenase D (SDHD)-mutation, but limited - 54 -
18F-DOP A PET for localizing tumors causing catecholamine excess sensitivity and specificity in the more common benign pheochromocytomas. 6, 8-10 More specific imaging of catecholamine­producing tumors is possible with the catecholamine precursor 6-[F-18]fluoro-L-dihydroxyphenylalanine (18F-DOPA) or the catecholamine 18F­fluorodopamine. Small studies have confirmed the feasibility of 18F-DOPA as tracer for staging of pheochromocytomas.10-13 18F-fluorodopamine showed an excellent sensitivity superior to 123I-MIBG, in a retrospective study in 53 patients with known or suspected benign and malignant pheochromocytomas.14 In a small study in 12 pheochromocytoma patients 
18F-DOPA PET has also shown good performance relative to 123I-MIBG scintigraphy.10 However, most studies in the past have based inclusion of patients on the (suspected) presence of a pheochromocytoma or paraganglioma. They have not addressed this issue from the even more basic clinical relevant question: a patient presenting with catecholamine excess. The aim of this prospective study was to investigate the sensitivity of 18F-DOPA PET to visualize lesions in a large group of patients with catecholamine excess compared with 123I-MIBG scintigraphy and CT/MRI. In addition we correlated 18F-DOP A PET findings with catecholamine plasma and urine markers. PATIENTS AND METHODS All consecutive patients with proven catecholamine excess who visited the UMCG, Groningen, between March 2003 and January 2008 were asked to participate in this study (Figure 1). Each patient underwent extensive biochemical analysis and conventional imaging with CT and/or MRI and 123I-MIBG in the UMCG or the referring hospital, and an 18F­DOPA PET scan in the UMCG. Data for age, gender, medication, biochemical measurements, the presence of genetic mutations (succinate - 55 -
Chapter 3 dehydrogenase B (SDHB), SDHD, von Hippel Lindau (VHL), neurofibromatosis type 1 (NFl) and the rearranged during transfection (RET)-gene) and histology were collected. Patients were classified as having malignant disease in case of recurrence or presence of metastases. The study was approved by the local medical ethics committee. All patients or their legal representatives gave written informed consent. 
1231-MIBG and 18F-DOPA PET imaging 123I-MIBG imaging was performed according to guidelines of the Dutch Society of Nuclear Medicine.15 In brief, before administration of 123I­MIBG (200-370 MBq) medication interfering with 123I-MIBG-uptake has to be stopped and thyroid uptake of possibly formed free 123I is blocked with sodium or potassium iodide or perchlorate. Planar whole-body images are acquired 24 hours after injection of 123I-MIBG, but can additionally be performed at 4 and 48 hours after injection. In case SPECT images are performed, this is done at 24 hours after injection. 18F-DOPA was locally produced as described previously.16 Patients, allowed to continue all medication, fasted for 6 hours before the examination. Whole-body 2D-PET images were acquired 60 minutes after the intravenous administration of 18F-DOPA (180 ± 50 MBq), on a Siemens ECAT HR+ positron camera (Siemens, Knoxville, TN) with attenuation correction (7 - 10 bed positions of 5 minutes emission and 3 minutes transmission scan, total scanning time approximately 60 minutes). Images were reconstructed using the OSEM algorithm 8 subsets, 2 iterations. For the reduction of tracer decarboxylation, subsequent renal clearance and to increase tracer uptake in tumor cells patients received 2 mg/kg carbidopa orally as pre-treatment 1 hour prior to the 18F-DOPA injection.12, 17, 18 - 56 -
18F-DOP A PET for localizing tumors causing catecholamine excess 
CT/MRI In all patients either CT or MRI were performed, based on the preferences of the treating physician. CT-examinations were performed using a spiral or multislice scanner, both before and after administration of intravenous contrast agent. MRI-examinations were performed on a 1.5 Tesla scanner using various Tl and T2-weighted sequences, including series after administration of an intravenous gadolinium agent. In the majority of MRI-examinations in- and opposed phase Tl-weighted sequences were available. Reconstructed slice thickness varied between 3-10 mm. In accordance with current clinical practice and to keep radiation exposure low, all patients had their upper abdomen scanned and if there was suspicion of lesions elsewhere, the involved body region was also analyzed. Image interpretation One nuclear medicine physician (AHB), blinded for other imaging and biochemical information, interpreted the 123I-MIBG scans and 18F­DOP A PET scans during separate reading sessions. Lesions were graded semi-quantitatively using liver uptake (LU) as reference (scores: 0 = uptake absent; 1 = uptake less than LU; 2 = equal to LU; 3 = moderately more intense than LU; 4 = markedly more intense than LU) (19). Lesions were classified as positive using the following criteria: adrenal uptake more intense than LU (score 3-4) and any non-physiologic extra-adrenal focal uptake. Scans were considered positive if at least one positive lesion was found. We determined a 'whole-body metabolic burden' (WBMB) to serve as an image-derived index for overall tumor activity per patient.20 In order to make the WBMB independent of body weight and injected dose, standardized uptake values (SUV) were used.21 For each tumor lesion the metabolic burden (MB) was calculated as: - 57 -
Chapter 3 MB = SUV mean X volume. The WBMB was calculated as the sum of the MB of each tumor lesion in the PET image. Both SUVmean and tumor volume were obtained from the PET image using a volume of interest (VOi) that was defined as the tumor volume enclosed by a 40% isodensity surface.22 All CT and MRI scans were assessed by a radiologist, (MEJP) blinded for all other imaging and biochemical data. Adrenals were classified as normal, hyperplastic or suspect for pheochromocytoma. Other lesions were graded as benign or metastatic tumor. Criteria for classifying a lesion as pheochromocytoma were: a hyperintense signal on T2-weighted MRI images, strong enhancement after gadolinium administration, enhancement with intravenous contrast on CT, localization, size ( of adrenal gland or lymph node) and infiltrative growth pattern.4 Enhancement at CT and MRI was visually noted, comparing the series before and after administration of the contrast agent. Level of certainty was expressed on a scale of 1-5 (1 = not tumor, 2 = probably not tumor, 3 = equivocal, 4 = probably tumor, 5 = definitely tumor). Lesions with scores of 4 and 5 were regarded as positive findings. CT and MRI data were analyzed together. Composite Reference standard As a composite reference standard for presence of tumor lesions, all available clinical information on cytology, histology, follow-up and imaging (CT/MRI, 1231-MIBG and 18F-DOPA PET) was used.23, 24 This is considered the optimal gold standard, as cytological or histological verification of every lesion is neither feasible nor justifiable in these patients. Whenever possible, new findings on PET were verified with additional investigations. 
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18F-DOP A PET for localizing tumors causing catecholamine excess Biochemical markers Concentrations of markers of catecholamine metabolism, i.e. normetanephrine, metanephrine and 3-methoxytyramine were determined in plasma (free fractions) and in a 24-h urine sample (total fractionated metanephrines) (upper reference limits of metanephrine, normetanephrine, 3-methoxytyramine are 1.0 7, 0 .33, 0 .17 nmol/liter in plasma and 260 , 99, 197 µmol/mol creatinine in urine, respectively) as described earlier.25, 26 Serum concentrations of chromogranin A were measured using a radioimmunoassay (Cga-React, Cis Bio International, Marcoule, France) (upper limit 10 0 mg/liter). Catecholamine-producing tumors can produce either predominantly norepinephrine or epinephrine. Metanephrine concentrations in plasma and urine were used to determine catecholamine-secretion phenotype, as described earlier.27 Effect on treatment All imaging modalities were considered for treatment decisions and all treatments were documented. In particular, it was evaluated whether additional information provided by 18F-DOPA PET had changed treatment decisions. Treatment for pheochromocytoma and paraganglioma consisted of surgery for benign pheochromocytomas or solitary recurrence, according to international guidelines.5, 28 Surgical debulking of malignant tumors was performed if technically possible, and additional palliative medical treatment was given, including 131I-MIBG administration for metastatic MIBG-positive lesions.5 Data and statistical analysis The routine clinical use of 18F-DOP A PET was considered to be of relevance in case sensitivity would increase from 71 % (estimated sensitivity 
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Chapter 3 for 123I-MIBG based on the comparative study by Hoegerle10) to 95% with 
18F-DOPA PET, using McNemar's test for comparison with 90% power, with a discordancy rate of 24% 18F-DOPA PET-positive but 123I-MIBG­negative patients and 2% of patients positive on 123I-MIBG scintigraphy but negative on 18F-DOPA PET and P < 0.05, two-sided. The required number to study this was calculated to be at least 43 patients. Analysis was performed at the level of individual patients and individual lesions, both for the total group of patients and for subgroups based on benign vs. malignant pheochromocytoma and hereditary vs. non­hereditary tumors. If the number of lesions in one region exceeded five, the number of lesions was truncated at five lesions for that region to avoid bias when calculating sensitivity.23, 24 1 8F-DOPA PET and 123I-MIBG scintigraphy are whole-body modalities, while CT and MRI are primarily directed at the areas of clinical interest. In order to eliminate bias towards whole-body imaging methods, only body areas for which all three imaging modalities were available, have been evaluated for sensitivity calculations. Patient-based sensitivity was determined as the number of patients with a positive test (at least one lesion detected) divided by the total number of patients. Lesion-based sensitivity was calculated as the number of positive lesions by an individual technique divided by the total number of lesions using the composite reference standard, both for the total group of patients and for subgroups. For correlations, Spearman's r test was calculated. A P value was considered significant in case of values < 0.05, two-sided. Statistical tests were performed using the SPSS package version 14.0 - 60 -
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RESULTS Patient characteristics Forty-eight patients were screened and included (Figure 1, Table 1). In 43 patients SPECT 123I-MIBG was performed. No patients used medication known to interfere with 123I-MIBG-uptake around the time of imaging.29 Median time between 18F-DOP A PET and 123I-MIBG was 19 days. All scans were performed within 3 months, except for one patient with a 121 day interval. In addition to CT /MRI of the upper abdomen, CT /MRI of the lower abdomen was performed in 40 patients, CT /MRI of the thorax in 14 and of the head and neck in three. Genetic testing was performed in 32 patients. 
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hyperplasia Figure 1. Flow diagram schematically showing patient recruitment. - 61 -
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Table 1. Patient characteristics (n = 48) 
Characteristics Sex (N of patients) male/female Median age in years (range) MEN2aNHL/NFl/SDHD/SDHB (N of patients with genetic mutation) Value 20/28 46 (5 - 79) 7/3/2/1/2 Suspected tumor/known tumor 30/18 Adrenal/Extra-adrenal tumor (N of patients) 42/3 Benign/Malignant tumor (N of patients) 24/21 Adrenergic/Noradrenergic phenotype (N of patients) 32/16 Biochemical analysis (median, range) Urinary normetanephrine (µmol/mol) (N = 44) 540 (44 - 18,704) Urinary metanephrine (µmol/mol) (N = 44) 200 (14 - 9229) Urinary 3-methoxytyramine (µmol/mol) (N = 36) 184 (47 - 3708) Plasma free normetanephrine (nmol/liter) (N = 3.8 (0.17 - 70.1) 30) Plasma free metanephrine (nmol/liter) (N = 30) Plasma free 3-methoxytyramine (nmol/liter) (N = 25) Chromogranin A (mg/liter) (N = 28) 
Patient-based analysis 
0.72 (0.01 - 27.5) 0.15 (0.01 - 6.8) 87 (15 - 4250) 
18F-DOPA PET was positive in 43 patients, 123I-MIBG in 31 and CT /MRI in 32 .. Patient-based analysis showed 18F-DOP A PET to be superior in identifying affected patients compared to 123I-MIBG (P < 0.01) and versus CT/MRI (P < 0.01) as it had the highest sensitivity (Table 2). A representative patient is shown in Figure 2. There was no statistically significant difference between the sensitivity of 123I-MIBG and CT/MRI (P = 1 .0). 
- 62 
18F-DOP A PET for localizing tumors causing catecholamine excess Table 2. Patient based analysis of imaging performances CT/MRI 18F-DOPA PET 
1231-MIBG Number of patients with positive lesions/total number of patients 32/48 43/48 31/48 Sensitivity % (95% CI) 67% (52 - 80) 90% (77 - 97) 65% (49 - 78) Lesions were solely demonstrated by 18F-DOP A PET in nine patients and by 1231-MIBG in one. The clinical and biochemical characteristics, including ratios of the biochemical markers, of the three patients in whom all imaging modalities were negative were in the same range as from the patients with positive scans. 
A 
8 Figure 2. Imaging of a patient with a known metastatic pheochromocytoma. (A) 18F-DOP A PET shows increased uptake in the left adrenal gland and three lesions in the spine (arrows). (B) Fusion image of 18F-DOPA PET and CT shows uptake in the region of the left adrenal gland, without anatomical substrate. (C) CT image of the region of the left adrenal gland. 1231-MIBG imaging was negative (not shown). 
- 63 -
Chapter 3 Lesion-based analysis A total of 124 lesions were detected by all imaging methods together. Seventeen patients had one lesion, eight had two, three had four and four patients had five or more lesions. In lesion-based analysis, 18F­DOP A PET had the highest sensitivity compared to the other imaging modalities (Table 3) (18F-DOPA PET (P < 0.001) vs. 123I-MIBG and vs. CT/MRI (P < 0.001)). Performance of 123I-MIBG and CT/MRI did not differ 
(P = 0.51). In addition, the combination of 18F-DOPA PET and CT/MRI had the highest sensitivity (93%) for detecting tumor lesions, as CT/MRI detected lesions missed by nuclear medicine techniques and vice versa. The sensitivity of the 18F-DOPA PET/CT/MRI combination was higher than the combination of 123I-MIBG and CT/MRI (sensitivity 94 vs. 76%, P < 0.001). 
18F-DOPA PET showed more lesions in 23 patients, while 123I-MIBG performed better in three patients, all three with malignant pheochromocytoma. In 18 patients both methods showed the same number of lesions. We observed no difference in regional sensitivity for the detection of metastases for the different techniques. Lesions missed by 18F­DOP A PET were mostly abdominally or retroperitonally located, size ranging from 12-24mm. Except for one adrenal pheochromocytoma of 18 mm, none of these lesions was histologically verified. CT /MRI missed mainly adrenal lesions < 2cm, especially in patients with hereditary disease or local recurrence, and ossal lesions. Sensitivities in subgroups of patients with benign or malignant pheochromocytoma and in patients with hereditary or non-hereditary disease showed that 18F-DOPA PET is superior to 123I-MIBG or CT/MRI in all subgroups (Table 3). The performance of imaging modalities did not differ significantly between benign and malignant pheochromocytoma and hereditary and non-hereditary pheochromocytoma. The clinical and biochemical characteristics, including ratios of the separate biochemical markers, of the three patients in whom 123I-MIBG was superior to 18F-DOPA PET were not different from the other patients with malignant - 64 -
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Chapter 3 pheochromocytoma. Neither catecholamine-secretion phenotype, nor serum chromogranin-level predicted scan performance. Treatment consisted of surgical resection of primary tumor (n = 27) or metastases (n = 5) in a total of 32 patients and surgery combined with 
131I-MIBG-therapy in three, 131I-MIBG-therapy alone in three, chemotherapy in one, symptomatic medical therapy in three and watchful waiting in six. Final diagnosis (by histology) was pheochromocytoma in 40 patients, adrenal hyperplasia in two, paraganglioma in two, ganglioneuroma in one, and remained unknown in three since no lesions were detected. The latter three patients presented with typical complaints of pheochromocytoma and a catecholamine excess, but until now no tumor could be localized. Imaging with 18F-DOPA PET influenced treatment decisions in 14 patients (29%). It localized solitary tumors (n = 7), indicated the neuroendocrine nature of inconclusive lesions on CT/MRI (n = 2) or inconclusive uptake on 123I-MIBG (n = 2), resulting in the decision to proceed to surgical resection (Figure 3). In three patients surgery was cancelled because of multiple otherwise unknown metastases. Removed lesions (n = 7) that were only visible on 18F-DOP A PET were all histopathologically confirmed to be neuroendocrine tumor. Correlations between PET imaging and catecholamine metabolism Biochemical characteristics (Table 1), including ratios of the biochemical markers, did not differ between patients with benign and malignant pheochromocytoma. Median SUVmax was 3.2 (range: 1.3 - 31.9), while median SUVmean was 2.2 (0.88 - 19.8). Median total tumor volume was 11.3 cm3 (0 - 515 cm3) .  Together they resulted in a median WBMB of 65 (0 - 3229) cm3• The WBMB correlated with the 24-h urinary excretion of total (free +conjugated) normetanephrine (r = 0.84, P < 0.001), metanephrine (r = 0.57, P < 0.01), and 3-methoxytyramine (r = 0.65, P < 0.01) as well as plasma free - 66 -
18F-DOP A PET for localizing tumors causing catecholamine excess levels of normetanephrine (r = 0.82, P < 0.001), 3-methoxytyramine (r = 0.51, P = 0.01) and chromogranin A (r = 0.49, P < 0.01) .  
A B C D 
• •  Figure 3. Patient with bilateral pheochromocytoma. (A) 18F-DOPA PET shows increased uptake in both adrenal glands. (B) 1231-MIBG imaging: asymmetric 1231 uptake in the adrenals: the left adrenal shows markedly increased uptake, whereas uptake in the right adrenal can easily be mistaken as physiological. (C) Fusion of 18F-DOP A PET and MRI shows uptake in both adrenal glands. (D) MRI showing the left adrenal pheochromocytoma. DISCUSSION This study compared the performance of 18F-DOPA PET and 1231-MIBG scintigraphy and CT/MRI in patients with catecholamine excess, and found that 18F-DOP A PET was superior to all other modalities. In addition, 
18F-DOPA PET plus CT/MRI was superior to 1231-MIBG scintigraphy plus CT/MRI. 18F-DOPA PET plus CT/MRI was found to be the optimal combination of imaging procedures to localize catecholamine-producing tumors. Furthermore, we showed that WBMB, measured with 18F-DOP A PET, correlated with metabolic tumor activity, determined with biochemical markers. 
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Chapter 3 In this study we have addressed the problem of imaging of catecholamine-producing tumors from the most basic clinical relevant question. Therefore, we included all patients with proven catecholamine excess and not just patients with a (suspected) pheochromocytoma or paraganglioma. The most common final diagnosis in our study was pheochromocytoma, while only a few patients had another diagnosis. Since all diagnostic techniques have their limitations, it is possible that tumor lesions in the three patients with negative imaging studies were still too small to be visualized or that the biochemical tests were false-positive.30 As pheochromocytoma and paraganglioma together constitute the majority of catecholamine-producing tumors, most imaging studies are performed in patients with known pheochromocytoma and paraganglioma. To our knowledge, no studies investigating PET imaging in ganglioneuroma have been performed.31 Previous small studies (9 to 25 patients) have reported sensitivities ranging from 50-100% for 18F-DOP A PET in pheochromocytoma and paraganglioma.10-13 In the present study in the patients with benign (n = 21) and malignant (n = 19) pheochromocytoma, both on a patient and lesion­based level, we observed excellent sensitivities for 18F-DOP A PET (95% patient-based and 85% lesion-based). This contrasts with previous studies in 9 to 30 patients that have reported lower sensitivity for PET with 18F­DOP A or 18F-fluorodopamine in metastatic pheochromocytoma and paraganglioma. 6, 11, 12 These previous findings have stimulated the use of the broader imaging tracer 18F-FDG PET, which visualizes glucose metabolism, and 18F-FDG PET has been suggested to be superior for imaging of metastatic pheochromocytoma or paraganglioma, especially for patients with an underlying SDHB-mutation. It has been demonstrated that 18F-FDG PET can detect malignant pheochromocytoma and paraganglioma lesions that are missed on imaging with more specific tracers like 18F-DOP A.6, 11 However, 18F-FDG PET is not suitable as first-line tracer in patients presenting with catecholamine excess, in view of a low sensitivity (58% in 
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18F-DOP A PET for localizing tumors causing catecholamine excess 12 benign pheochromocytoma).8 In addition, although 18F-FDG PET was found to be superior to 18F-fluorodopamine PET in two groups of 30 patients with a SDHB-mutation, the latter performed better in 41 metastatic SDHB-negative patients.6, 32 The excellent sensitivity of 18F-DOPA PET for metastatic disease in our study may be due to the fact that only two patients were SDHB-mutation positive in our study, compared to 45 - 100% of the patients in previous studies.6, 12 Handling of the tracer by the tumor cell may well explain why 18F­DOP A is a more suitable tracer for catecholamine-producing tumors than 
18F-fluorodopamine. 18F-DOP A is transported into the cell by the large amino acid transporter 2 (LAT2), than decarboxylated by aromatic-L-amino acid decarboxylase (AADC) to 18F-fluorodopamine and transported into storage vesicles by VMAT. This pathway is active in many neuroendocrine tumors, making 18F-DOP A suitable to image a wide range of neuroendocrine tumors. 18F-fluorodopamine is transported into the cell not by LAT2 but by the dopamine transporter DAT, and thereafter immediately transported into storage vesicles by VMAT. The fact that LAT2 is constitutionally expressed in all cells, and AADC is highly expressed by most neuroendocrine tumors, whereas VMAT and DAT are variably expressed, potentially explains why 18F-DOP A could perform superior to 18F-fluorodopamine.33-35 In our study 18F-DOPA PET improved staging by detecting 36 unkown lesions and changed treatment decision in 14 patients. This suggests that routine implementation of 18F-DOPA PET in patients with catecholamine excess is likely to influence patient management. Pretreatment with carbidopa has been shown to increase the tumor­to-background ratio of tracer uptake.12, 18, 19 This has lead to an enhanced sensitivity of 18F-DOPA PET for pheochromocytomas and paragangliomas.12 In the other studies of 18F-DOPA PET in pheochromocytomas and paragangliomas no carbidopa pre-treatment was given10, 11 or only in a small number of patients, without mentioning the - 69 -
Chapter 3 effect of carbidopa in these patients.13. We feel that all studies with 18F­DOP A PET should be performed with carbidopa to maximize the potential of this imaging technique. The correlation between WBMB measured with 18F-DOPA PET and biochemical activity of catecholamine-producing tumors, as determined with biochemical markers, confirms that uptake of the catecholamine precursor 18F-DOP A is enhanced by overactivity of the catecholamine synthesis pathway and illustrates the tumor burden.36 Noradrenergic tumors secrete more catecholamines than adrenergic tumors of comparable size.27, 37 This might explain why we found stronger correlations between tumor burden and normetanephrine than metanephrine, in accordance with previous studies, which used tumor diameter27 and tumor mass37 as a measure of tumor burden. However, one recent study did not find a correlation between SUV max and biochemical markers.13 In our opinion, this is not surprising for SUV max is not a marker that represents total tumor burden, but a single measurement point, representing the maximum uptake in one single voxel. Biochemical markers on the other hand do represent a total tumor burden. WBMB, as used in our study, is a more real marker of tumor burden, than SUV max. Therefore it is not surprising to find a correlation between biochemical markers and WBMB. Shortcomings of this study are the fact that only three patients with extra-adrenal tumors were included. Furthermore, not all lesions were histologically verified, which would be the optimal gold standard, since we feel histological verification of every lesion is neither feasible nor justifiable in these patients. In conclusion, 18F-DOPA PET is superior to both 123I-MIBG scintigraphy and CT/MRI for the localization of catecholamine-producing tumors. The combination of 18F-DOPA PET and CT/MRI is most informative in the diagnostic work-up of patients with catecholamine excess. 
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Chapter 4 ABSTRACT Objective: Thus far one patient with a cardiac metastasis from an islet cell tumor has been reported. This is likely an underestimation due to restrictions of the used imaging methods and a lack of awareness of their possible existence. 11C-5-hydroxytryptophan positron emission tomography 
(11C-5-HTP-PET) fused with CT is currently the most sensitive imaging technique to detect islet cell tumors, which may identify cardiac metastases in these patients. Design & Patients: A renewed analysis of all 11C-5-HTP-PET scans performed in patients with metastasized islet cell tumors was performed between October 20 0 5  and July 20 0 9. When lesions suspect for cardiac metastases were identified with 11C-5-HTP-PET, chest-CT scans were reviewed and fused with the 11C-5-HTP-PET scans. Setting: University hospital Main outcome measure: Myocardial uptake on 11C-5-HTP-PET suspect for cardiac metastases Results: Five of 26 patients (19%) had �1 lesion suspect for cardiac metastases on 11C-5-HTP-PET. None showed symptoms of cardiac involvement. One cardiac lesion was also discernible on CT after fusion with PET. These CT scans, not ECG-gated, provided suboptimal information. Three of five patients with and 12 of 14 patients without cardiac metastases showed ECG-changes. Conclusion: Cardiac metastases of islet cell tumors are likely more frequent than currently observed. Increased awareness is necessary when evaluating - 76 -
Myocardial metastases of islet cell tumors visualized by 11C-5-HTP PET 
these patients for metastatic disease. Cardiac metastases may best be 
identified with 11C-5-HTP-PET. 
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Chapter 4 INTRODUCTION Pancreatic islet cell tumors are rare neoplasms of the pancreas, originating from the pancreatic islet cell lineage and can be associated with a clinical syndrome due to hormone hypersecretion. At the time of diagnosis approximately 50% of islet cell tumors have already metastasized, especially to the liver.1 However, when evaluating a patient for metastases, the heart is seldom considered. Based on the information from the literature myocardial metastases are rare as only one case of myocardial metastases from an islet cell tumor has been reported.2 Also the incidence of metastases in the heart in carcinoid tumors, a similar low grade neuroendocrine tumor, is considered to be low.3 However, the low incidence can well be an underestimation due to the restrictions of the used imaging methods. We have reported a case where myocardial carcinoid metastases were identified by imaging with the catecholamine precursor 6-fluoro­[18F]L-dihydroxyphenylalanine positron emission tomography (18F-DOP A PET), but not by conventional imaging.4 In addition, we recently discovered a patient with an islet cell tumor that showed cardiac metastases on 11C-5-hydroxytryptophan (1 1C-5-HTP) PET, alerting us to the possibility that the prevalence of cardiac metastases in these patients might be higher than suspected. It is possible that in patients with islet cell tumors, similar to carcinoid patients, the number of myocardial metastases is underestimated due to the lack of sensitive imaging modalities. 11C-5-HTP PET scanning is based on the intrinsic property of neuroendocrine tumors to take up, decarboxylate, and store amine precursors, such as the serotonin precursor 11C-5-HTP. This technique is currently considered as the most sensitive imaging modality for diagnosing islet cell tumors (up to 100%), being superior to 18F-DOPA PET and somatostatin receptor scintigraphy.5 In nuclear medicine, 6-[fluoride-
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Myocardial metastases of islet cell tumors visualized by 11C-5-HTP PET 18]fluorodeoxyglucose (18F-FDG) is the most widely used PET tracer for the imaging of tumors. This tracer visualizes tissue with increased glycolysis, such as tumor, but also in a number of other tissues such as the heart or the brain. Against such a strong physiological background pathological uptake due to metastases is only very rarely discernible. Therefore, nuclear medicine physicians are not accustomed to look for, and find, metastases in the heart. We decided to re-analyze all patients with metastasized islet cell tumors that underwent 1 1C-5-HTP PET with regard to myocardial metastases, including those patients reported earlier in a publication.5 
PATIENTS AND METHODS Since October 2005 11C-5-HTP PET is available for imaging of islet cell tumors in the University Medical Center Groningen. Until July 2009 154 
11C-5-HTP PET scans had been performed, 97 of which for (suspected) islet cell tumors. From a database of all 11C-5-HTP PET scans performed in the University Medical Center Groningen between October 2005 and July 2009 all patients with an islet cell tumor that had received a 11C-5-HTP PET scan, were identified. The 11C-5-HTP PET scans of all patients, which showed metastasised disease, were reviewed with thorough inspection of the heart by an experienced nuclear medicine specialist (A.H.B.). Focal increased uptake in the heart, which was higher than the normal diffuse, slight uptake in the myocardium was considered as suspect for cardiac metastases. Both conventional whole-body images and short and long axis reconstructions were reviewed. For all patients standardised uptake values (SUVs) were determined as a measure of tumor tracer uptake. A volume of interest (VOi) was semi­automatically drawn over the whole heart, including suspected cardiac lesions. SUVs were calculated using the formula: SUV = activity - 79 -
Chapter 4 concentration [MBq/ml] / injected dose per gram [MBq/g]. SUVmax was defined as the pixel with the highest 11C-5-HTP-uptake in the VOL In case of patients with suspect cardiac lesions, SUVmax over the heart was SUVmax of the lesion, as this was the hottest area in the heart. If more than one suspect cardiac lesion was seen, then the SUVmax of both lesions was measured, in which case the highest SUVmax was taken as the SUVmax over the heart. SUVmean was obtained from the PET image using a VOI that was defined as the tumor volume enclosed by a 70% isodensity surface. SUVmean was calculated as the mean SUV of all pixels with an activity of 70 to 10 0% of the SUVmax within the VOL The SUVmax over the heart was divided by the SUVmean to determine a ratio as a measurement of heterogeneity/homogeneity of cardiac uptake. All patients had, as part of their tumor staging, also undergone a computer tomography (CT) scan of the chest at the same time, that were reviewed by an experienced radiologist (K.V.J.M.V.). In addition, the CT scan was, if possible, fused with the 1 1C-5-HTP PET scan. The resulting images were discussed in a multidisciplinary setting. The charts of the selected patients were reviewed for data on clinical follow up, cardiac risk profile (including hypertension, diabetes, dyslipidaemia and a history of cardiovascular disease) and standard twelve-lead electrocardiograms (ECGs). The ECGs (MAC 50 0 ,  General Electrics, the Netherlands) were recorded by certified technicians with patients in supine position. ECGs were examined by a cardiologist blinded for the data to determine rhythm, heart rate, QRS axis, PR interval, QRS duration, QT­interval, and ST segment. ECGs could show more than one abnormality. Data of 17  patients from the present analysis were reported earlier by us.5 However, data on the heart had in retrospect not been examined so thoroughly. Patients participated in that study evaluating the diagnostic sensitivity of 11C-5-HTP PET and 18F-DOPA PET in patients with carcinoid tumors and islet cell tumors. The study was approved by the medical ethical committee, all patients gave informed consent. 
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Myocardial metastases of islet cell tumors visualized by 1 1C-5-HTP PET 
11C-5-HTP was produced locally as described earlier.6 Patients fasted for 2 h before the examination. For the reduction of tracer decarboxylation and subsequent renal clearance and to increase tracer uptake in tumor cells all patients received 2 mg/kg carbidopa orally as pre-treatment 1 h prior to the 11C-5-HTP injection.7 - 9 Whole body 2D-PET images were acquired 10 min after the intravenous (IV) administration of 11C-5-HTP (200 - 400 MBq, with an estimated mean radiation dose of 0.34 mSv per 100 MBq) on a Siemens ECAT HR+ PET camera (Siemens) with attenuation correction (7-10 bed positions of 5 min emission and 3 min transmission scan). CT of the chest (4-16 slice, Siemens Somatom Sensation) with an estimated mean radiation dose of 8-20 mSv[lO] was performed using oral contrast and IV contrast (Visipaque, 120 mL, 2.5 mL/s) enhancement. The reconstruction interval was 0.75-10 mm. 
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Myocardial metastases of islet cell tumors visualized by 11C-5-HTP PET in the group of patients without focal myocardial uptake on the 11C-5-HTP PET scan had a typical cardiac risk profile, while none of these patients had a history of cardiac disease. The cardiac metastases in all patients showed relatively low uptake of 11C-5-HTP in comparison to the other lesions. Median cardiac SUVmax and SUVmean in hearts without possible metastases were lower than in patients with suspect cardiac lesions on 11C-5-HTP PET (Table 2). This resulted in a higher SUVmax/SUVmean ratio in the latter group, suggesting less homogenous uptake of 11C-5-HTP. Three out of five patients with possible cardiac metastases had atypical changes on their ECG, i.e. sinus tachycardia (n=l), left axis (n=l), premature ventricular complexes (n=l), diffuse negative T-waves (n=l), and U-wave (n=l). In 14 out of 21 patients without possible cardiac metastases on the 11C-5-HTP PET scan, an ECG was available. 
Table 2. Cardiac SUVs (including the possible cardiac lesions) on 11C-5-HTP PET SUVmax (whole heart): median (range) SUVmean: median (range) SUVmax suspect lesions: median (range) SUVmax/SUVmean ratio: median (range) SUV: standardised uptake value Patients without suspect cardiac uptake 1 .9 (1 .1-3.0) 1 .7 (1 .0-2.6) 1 .1 (1.1-1 .2) Patients with suspect cardiac uptake 2.6 (1 .9-4.8)* 1 .7 (1 .4-2.2) 2.6 (1 .9-4.8) 1 .4 (1 .3-2.3) *In these patients cardiac SUVmax is the SUVmax of the hottest cardiac lesion. A total of two ECGs of these patients were without changes. Observed changes were atrial fibrillation (n=l), sinus tachycardia (n=2), sinus bradycardia (n=3), premature ventricular complexes (n=l), left axis (n=l), right axis (n=l), right bundle branch block (n=2), QT-interval prolonging - 83 -
Chapter 4 (n=3), and U-wave (n=9). None of these patients took any medication that might have caused the ECG changes. Three patients had clear focally increased uptake in the heart region on the 
11C-5-HTP PET scan, while two had equivocal lesions. Short and long axis reconstructions did not render clearer results than conventional whole­body images due to lack of counts in the field of view. In one patient the cardiac lesions were also discernable on the CT scan after fusion of the 11C-5-HTP PET images with the CT images (Figure 1). 
A B Figure 1. Patient 3 A. 11C-5-HTP PET scan showing two cardiac metastases 
(arrows), both confirmed by CT scan, and extensive liver metastases. Diffuse 
physiological uptake in the pancreas and excretion via the kidneys, ureters and 
bladder. B. Fusion image of CT and 11C-5-HTP PET showing one of the cardiac 
metastases. Even though CT scans of the chest were available for all patients with suspected cardiac metastases, they were not ECG-gated. Considering the limitations due to slice thickness and the presence of movement artifacts which obscured the images or the fact that the heart had only partly been scanned they allowed only suboptimal interpretation of the - 84 -
Myocardial metastases of islet cell tumors visualized by 11C-5-HTP PET heart. As a result of this, no other cardiac lesions could be confirmed with CT. In patient 2 echocardiography was performed when the 11C-5-HTP PET scan indicated possible cardiac involvement, but this failed to confirm the presence of cardiac metastases. Cardiac MRI was not possible due to pedical screws placed in the thoracic spine following corporectomy for a metastasis in vertebrae Thl. Unfortunately, because of the retrospective nature of this study, patients 4 and 5 had already died at the time of this analysis and no autopsy was performed, leaving only the CT scans available for evaluation. Patient 1, 2, 3 are currently still in follow-up. Patient 4 died acutely at home, while patient 5 died due to progression of disease. DISCUSSION In this study we systematically investigated the presence of cardiac metastases in patients with an islet cell tumor using the most sensitive technique, namely 11C-5-HTP PET, for imaging of islet cell tumors and argued that cardiac metastases in patients with islet cell tumors are likely more frequent than reported in literature. We showed that when doctors are aware of the possibility of cardiac metastases and consequently thoroughly inspect the heart, lesions suspect for cardiac metastases can be found. Metastases to the heart are not frequently discovered in cancer patients premortem. However, in postmortem studies cardiac metastases are found in up to 25% of all cancer patients.11 [ The low premortem detection rate can either be explained by the fact that 90% of cardiac metastases are clinically silent12, 13 and/or by the fact that they are underestimated due to the restrictions of the commonly used imaging methods, as the vast majority of these metastases is small.3, 11 The combination of these factors has lead to a lack of awareness of physicians concerning the presence of cardiac metastases in cancer patients. - 85 -
Chapter 4 For the detection of cardiac metastases regardless of tumor type echocardiography is recommended.12 However, lesions smaller than 1.0 cm are difficult to identify with echocardiography.3 Pericardia! effusion, another sign of metastases, is non-specific. This might be the reason that echocardiography is not routinely performed in the diagnostic work-up of patients with islet cell tumors. Other possible diagnostic imaging methods to detect cardiac metastases are CT and MRI. A drawback of these methods is the necessity of synchronizing data acquisition to the cardiac cycle to ensure optimal visualization of the heart, which can be achieved by ECG gating.14 However; ECG gating is not routinely performed for tumor staging scans, as was the case in our patients. The resulting imaging artifacts make identification of cardiac metastases difficult and thus radiologists are not accustomed to look for them in routine staging scans. For islet cell tumors we have the unique possibility of a tracer to specifically visualize the neuroendocrine tumor cell metabolism. The result is little interfering physiological uptake and clear tumor visualization, also within the heart. Given the high sensitivity of 11C-5-HTP PET for the detection of islet cell tumors in general5 and keeping in mind the limitations of conventional imaging for cardiac imaging, 1 1C-5-HTP PET can likely detect more myocardial metastases than conventional imaging. When lesions suspect for myocardial metastases of an islet cell tumor are found on 1 1C-5-HTP PET, conventional imaging specifically directed on the heart can be performed for confirmation. In this, 11C-5-HTP PET/CT, if gated, may be an attractive option, since the imaging in one session allows for optimal fusion results. Alternatively, an additional cardiac MRI can be performed when suspicion is raised based on the 1 1C-5-HTP PET and is not readily confirmed by the CT data. We found ECG-changes in three out of five patients with cardiac metastases. These observed abnormalities were non-specific, i.e. we could not identify a relation between the location of the metastases and the observed abnormalities. On the other hand in twelve out of fourteen (86%) - 86 -
Myocardial metastases of islet cell tumors visualized by 11C-5-HTP PET patients without cardiac metastases ECG changes were also observed. In contrast to carcinoid tumors, islet cell tumors rarely produce serotonin.15 Thus, without cardiac metastases, patients with an islet cell tumor have a chance similar to that of the general population to display changed ECG­patterns. The majority of cancer patients with cardiac metastases have evidence of ECG changes, such as ST-T-wave-changes or arrhythmias.16 These ECG changes are most likely the result of mass lesions involving the myocardium or pericardium, possibly infiltrating the conducting system.11, 
12, 16 However, these are frequently asymptomatic, as only 1 % of all cancer patients with cardiac metastases develop clinical symptoms related to intracavitary or intramyocardial metastases.17 When left untreated, these may eventually lead to a 'sudden cardiac death.18 In this light the QT­interval prolongation is of interest. In our patients without cardiac metastases a prolonged QT-interval (after correction for heart rate) U­waves on the ECG were more frequently observed. Therefore, we cannot underline a relation between cardiac metastases and cardiac arrhythmias due to QT prolongation. In few patients with an islet cell tumor an autopsy is performed to examine the conducting system and search for cardiac metastases as possible cause of death. Therefore, this cause of death may be more frequent than we know and should be considered. It has been reported that in patients with cardiac involvement the incidence of abnormal ECGs increased as death approached.19 Serial ECG recordings during follow-up and the relation with changes, such as the QT-interval, might identify patients at risk for sudden death. The discovery of cardiac metastases may thus have significant impact on the prognosis of an individual patient. In this study we could confirm the presence of cardiac metastases with CT in one patient. Even if not all islet cell tumor patients identified in this study would indeed have cardiac metastases, we still feel that they are far more common than previously reported. Considering the potential consequences, doctors should be more aware of the possibility of metastatic - 87 -
Chapter 4 involvement of the heart and should consider this when evaluating patients with a metastatic islet cell tumor. CONCLUSION This study shows that cardiac metastases of islet cell tumors likely occur more frequently than previously reported. Special attention should be paid to this when evaluating patients with metastatic disease of islet cell tumors. To identify patients with cardiac metastases a 1 1C-5-HTP PET scan may best be performed, as this is currently the most sensitive imaging technique to image islet cell tumors. Suspect lesions should then be verified by anatomical imaging with preferably ECG-gated MRI or CT. 
- 88 
Myocardial metastases of islet cell tumors visualized by 11C-5-HTP PET 
REFERENCES 1 Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72 2 Sparrow PJ, Kurian JB, Jones TR, et al. MR imaging of cardiac tumors. Radiographies 2005;25:1255-76 3 Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-1196 4 Fiebrich HB, Brouwers AH, Links TP, et al. Images in cardiovascular medicine: myocardial metastases of carcinoid visualized by 18F-dihydroxy­phenyl-alanine positron emission tomography. Circulation 2008;118:1602-1604 5 Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and llC-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008 ;26: 1489-1495 6 Orlefors H, Sundin A, Garske U, et al. Whole-body (ll)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005 ;90:3392-3400 7 Bergstrom M, Lu L, Marquez M, et al. Modulation of organ uptake of UC­labelled L-DOPA. Nucl Med Biol 1997;24:15-19 8 Neels OC, Koopmans KP, Jager PL, et al. Manipulation of [llC]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells. Cancer Res 2008;68:7183-7190 9 Orlefors H, Sundin A, Lu L, et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with llC-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:60-65 
- 89 -
Chapter 4 
10 International Commission on Radiological Protection: ICRP Publication 87: 
Managing patient dose in computed tomography. ICRP Online. Elsevier, 
2001. http://icrp.org 
11 Reynen K, Kockeritz U, Strasser RH. Metastases to the heart. Ann Oncol 
2004; 15:3 75-381 
12 Butany J, Nair V, Naseemuddin A, et al. Cardiac tumours: diagnosis and 
management. Lancet Oncol 2005;6:219-228 
13 Shapiro LM. Cardiac tumours: diagnosis and management. Heart 
2001;85:218-222 
14 Altbach MI, Squire SW, Kudithipudi V, et al. Cardiac MRI is complementary 
to echocardiography in the assessment of cardiac masses. Echocardiography 
2007;24:286-300 
15 O'Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg 
Oncol 2008;34:324-32. 
16 Cates CU, Virmani R, Vaughn WK, et al. Electrocardiographic markers of 
cardiac metastasis. Am Heart J 1986;112:1297-1303 
17 Roberts WC. Primary and secondary neoplasms of the heart. Am J Cardiol 
1997;80:671-682 
18 Shehata BM, Thomas JE, Doudenko-Rufforny I. Metastatic carcinoid to the 
conducting system-is it a rare or merely unrecognized manifestation of 
carcinoid cardiopathy? Arch Pathol Lab Med 2002;126:1538-1540 
19 Glancy DL, Roberts WC. The heart in malignant melanoma. A study of 70 
autopsy cases. Am J Cardiol 1968;21:555-571 
- 90 -
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Chapter 4a Carcinoids are rare tumors arising from neuroendocrine cells, which can produce and secrete hormones. Carcinoid disease may comprise cardiac involvement, with right-sided endocardial and valvular fibrous lesions of the heart.1 This so-called carcinoid heart disease may present with cardiac failure and arrhythmias. More uncommonly, myocardial metastases are diagnosed in carcinoid disease. The reported incidence of myocardial carcinoid metastases among patients with metastatic carcinoid disease is 4 %. 2 These metastases are usually discovered during screening for distant metastatic disease or carcinoid heart disease, but may also present with arrhythmias. However, the incidence may be underestimated as a consequence of limited resolution of the used imaging techniques. In the past, myocardial metastases have been located with ultrasonography and somatostatin receptor scintigraphy (SRS). Lesions smaller than 1.0 cm are difficult to identify with ultrasonography and although good sensitivity (92%) has been reported for SRS, it is by no means perfect.3, 4 New imaging techniques, such as the 18F-DOP A PET scan, can be of additional value in diagnosing these rare metastases of carcinoid disease, as shown in the following case report. A 60-year old man presented with diarrhea, abdominal pain and weight loss, but no cardiac complaints. Physical examination revealed no abnormalities apart from a slight hepatomegaly. Laboratory values showed mild anemia, an elevated serotonin level in platelets of 41 nmol/109 platelets (upper reference limit 5.4 nmol/109 platelets) and urinary 5-hydroxyindoleacetic acid level of 15.2 mmol/mol creatinine (upper reference limit 3.8 mmol/mol creatinine). SRS with planar imaging of the whole body and SPECT imaging of abdomen and chest 24 hours after injection of 200 MBq 111ln-octreotide showed uptake in abdomen, bones, ribs and left supraclavicular region (Figure lA). - 92 -
Myocardial carcinoid metastases 
A B 
• 
• Figure 1. A, SRS planar imaging of the whole body shows uptake in abdomen, skeletal lesions and left supraclavicular region. B, the 18F-DOP A PET scan shows uptake in the abdomen, bone metastases and two lesions in the heart . An 18F-DOPA PET scan revealed uptake in the abdomen, bone metastases and two lesions in the heart (Figure lB). The ECG showed a sinus bradycardia of 52 beats per minute during metoprolol for hypertension, but was otherwise normal (Figure 2). Echocardiography showed no tumor lesions and no abnormalities of right ventricular function or valves, indicative of carcinoid heart disease. An MRI of the heart demonstrated two myocardial lesions in the left ventricle. Fusion of 18F-DOP A PET and MRI confirmed the presence of two lesions in the left ventricular myocardium (Figure 3A). In retrospect, one myocardial lesion was also visible on SRS (Figure 3B; fusion of MRI and SRS). 
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2!:i:m s lt=:i:\' l50F.z Figure 2. ECG showing sinus bradycardia. \'1 ,·: 1 r_, I I A " /  � -1 ( -.} /'/ -- '. I - -- ... '11 /\,. ... -.,., 1/ ... .... I I . J ,/ \ ... __ J /\ . .  ·: I --- ., ,.,. I '  I I .I _.._. _ I -�. - ,  I /' . ..,r- • f }/· .. JL ,r..._ -J" J ,. ........ ____, / ,' - .J,,_ -- -Figure 3. A, fusion of 18F-DOP A PET and MRI confirms the presence of two lesions in the left ventricular myocardium. B, fusion of MRI and SRS shows only one myocardial lesion. Given the absence of cardiac problems, no surgical intervention was considered for the cardiac lesions. The primary ileal tumor was surgically removed and confirmed to be a carcinoid. Follow-up 18F-DOP A PET and - 94 -
Myocardial carcinoid metastases MRI scans one year later showed unchanged metastases including the cardiac lesions and no new metastases. PET scanning using the catecholamine precursor 18F-DOP A was recently shown to be of diagnostical value in carcinoid disease. Imaging with 18F-DOP A is based on the intrinsic property of neuroendocrine tumors to take up amine precursors, such as 18F-DOP A. The combination of this specific tracer with the high resolution provided by PET, shows an excellent sensitivity of detection of neuroendocrine tumor lesions (up to 96%), which is higher than the sensitivity with SRS in carcinoid patients.4 This can be explained by the limited spatial resolution and the lack of somatostatin-receptor expression in a number of tumors. Consequently, in carcinoid patients with cardiac complaints, a 18F-DOP A PET scan should be considered, to demonstrate or rule our myocardial metastases. The treatment for myocardial metastases usually consists of watchful waiting or surgical removal. Recently, a case of successful external beam irradiation has been reported. In our patient absence of complaints and stable cardiac lesions justify watchful waiting. 
- 95 -
Chapter 4a 
REFERENCES 1 .  Bhattacharyya S, Davar J, Dreyfus G, et al. Carcinoid heart disease. Circulation 2007;116:2860-2865 2. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-1196 3. Pandya UH, Pellikka PA, Enriquez-Sarano M, et al. Metastatic carcinoid tumor to the heart : echocardiographic-pathologic study of 11  patients. J Am Coll Cardiol 2002;40:1328-1332 4. Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan Positron Emission Tomography. J Clin Oncol 2008;26:1489-1495 
- 96 
Chapter 5 Combining 18F-DOPA and 18F-FDG PET for distinction of non-carcinoid malignancies in carcinoid patients Helle-Brit Fiebrich1 MD, Adrienne H. Brouwers2 MD, PhD, Klaas Pieter Koopmans2 MD, PhD, Elisabeth G. E. de Vries1 MD, PhD Departments of 1Medical Oncology, 2Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands European Journal of Cancer 2009, 45: 2312-2315 
Chapter 5 
ABSTRACT 
Aim Carcinoid patients frequently develop a second primary malignancy (SPM), which can deserve full treatment. Distinguishing a SPM from carcinoid lesions is therefore important. Differentiation can be achieved using the difference in uptake between different positron emission tomography (PET) tracers. Methods and Results Between January 2005 and August 2008 105 carcinoid patients were seen at the Department of Medical Oncology for treatment and follow-up. We identified 3 patients who presented with a new SPM in whom differentiation between carcinoid lesions and the SPM was guided by functional imaging of the catecholamine pathway with 6-fluoro-[18F]L­dihydroxyphenylalanine (18F-DOPA) PET and [18F]fluoro-2-deoxy-d­glucose (18F-FDG) PET as radiotracer for the glucose metabolism. All 3 patients had metastatic carcinoid disease and localised adenocarcinoma based on the PET-scans. For the adenocarcinoma they received curative treatment. Conclusion The difference in uptake between these PET techniques can be used for decision making when a primary or metastatic SPM is suspected. 
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Tumor type discrimination by PET imaging INTRODUCTION Carcinoids are rare neuroendocrine tumours. They often display a relative indolent behavior, resulting in a long survival. In up to 46% of patients with carcinoid tumours, another non-carcinoid primary malignancy is diagnosed.1 Given the relative long survival, even in case of metastatic disease, such a second primary malignancy (SPM) can deserve full treatment. Distinguishing lesions of a SPM from a carcinoid metastasis is therefore important, and may have therapeutic consequences. We will illustrate this in three patients in whom decision making was guided by functional imaging of the catecholamine pathway, with 6-fluoro-[18F]L­dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET) and [18F]fluoro-2-deoxy-d-glucose (18F-FDG) PET as radiotracer for the glucose metabolism. PATIENTS AND METHODS All carcinoid patients with metastatic disease seen between January 2005 and August 2008 at the Department of Medical Oncology for treatment and follow-up were included in this retrospective study. The charts of all patients were reviewed to identify patients that had presented with a new SPM during this period. The patients with a new SPM who received both a 18F-DOP A PET scan and a 18F-FDG PET scan to distinguish between the carcinoid lesions and the SPM in order to make a decision about possible curative surgery were further analysed. Clinical follow-up data of these patients were obtained. 
18F-FDG PET was performed as described previously.2 Since 2005 
18F-DOP A PET is available at the University Medical Center Groningen and is used as part of the routine work-up for staging of carcinoid tumours. 18F-
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Chapter 5 DOPA was locally produced.3 For the 18F-DOPA PET scan the patients fasted for 6 h before the examination and were allowed to continue all medication. Whole body 2D-PET images were acquired 60 min after the intravenous administration of 18F-DOPA (180 ± 50 MBq), on a Siemens ECAT HR+ positron camera (Siemens, Knoxville, TN) with attenuation correction (7-10 bed positions of 5 min emission and 3 min transmission scan, total scanning time approximately 60 min). Images were reconstructed using the OSEM algorithm 2 subsets, 8 iterations. One hour prior to the 18F-DOP A injection patients received 2 mg/kg carbidopa orally to increase tumour-to-background ratio of tracer uptake.4-6 
RESULTS Hundred five patients with a metastatic carcinoid tumour were identified, 49 men and 56 women with an average age of 62 years. Median follow-up since diagnosis of the carcinoid tumour was 3 years. Fifteen patients (14%) had an additional diagnosis of a SPM, most commonly located in the gastrointestinal tract (n = 4 patients) and the genitourinary tract (n = 4 patients). In 6 patients a metachronous carcinoid was detected 2 to 22 years after the non-carcinoid malignancy, while in 4 patients a synchronous, asymptomatic carcinoid was discovered during surgery for a non-carcinoid malignancy. In 5 patients a metachronous SPM was discovered 2-10 years after diagnosis of the carcinoid tumour was made. In 3 of these patients the SPM was diagnosed between 20 0 5  and 20 0 8, after 18F­DOP A PET became available in our hospital for the routine care of carcinoid tumours. These 3 patients underwent both a 18F-DOPA PET and a 
18F-FDG PET scan. Patient 1 is a 56-year old woman with a carcinoid of the ampulla of Yater was treated with a pancreaticoduodenectomy. Four years later, a -10 0 -






Figure 1. Patient 1 (a,b) : (a) On 18F-DOPA-PET one liver lesion (arrow). (b) 18F­
FDG-PET shows faint uptake in liver lesion, intense rectal-uptake (arrow). Patient 
3 (c,d): (c) 18F-DOPA-PET reveals four abdominally located metastases (arrows). (d) 
18F-FDG-PET showing uptake in left lung (arrow). Patient 3 is a 7 4-year old man with a carcinoid of the small intestine and metastases in liver and abdominal lymph nodes. One year later, on a routine chest CT scan, a previously unknown lesion suspect for lung cancer was discovered. This patient was a smoker. The 18F-DOP A PET showed - 102 
Tumor type discrimination by PET imaging uptake in a liver lesion and three abdominal lesions, while no lung uptake was observed (Figure le). SRS showed the same liver lesion as were also seen on 18F-DOPA PET and some vague uptake approximately in the midline of the abdomen on the site where the three abdominal lesions were seen on the 18F-DOP A PET scan and no lung uptake. However, the lung lesion did show up on 18F-FDG PET (Figure ld). It was concluded that the liver- and abdominal lesions originated from the carcinoid, and not from the pulmonary tumour. This lesion was surgically removed and histology showed a planocellular non-small cell lung cancer (NSCLC). Three years later still no signs of metastases of the lung cancer have been discovered. DISCUSSION The most common site of a SPM in carcinoid patients is the gastrointestinal tract, followed by the genitourinary tract and lung/bronchial system.7 SPMs are usually the more aggressive malignancy. Consequently, most patients with both a carcinoid tumour and a SPM die from the SPM. 1 Differentiation between metastases from either the carcinoid, or the SPM, may be difficult. Our findings illustrate that combining two different radiotracers for functional PET imaging can be helpful in these cases. Absence of proof of metastases of the adenocarcinomas supported the decision for surgery with curative intent in all cases. 18F-FDG PET imaging can detect fast-growing tumours with a high glucose metabolism (such as colorectal cancer and NSCLC), with a sensitivity of 95%.8 In contrast, tumours with a low metabolic rate (such as carcinoid tumours) often show faint 18F-FDG uptake and are poorly visualised by PET, with detection rates of 25-75%.9-15 Imaging with 18F-DOP A is based on the exclusive property of neuroendocrine cells to take up and decarboxylate amine precursors. An 
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Chapter 5 excellent sensitivity of 96% for detection of carcinoid tumour lesions is obtained with 18F-DOP A PET, which is higher than that of SRS. 16-18 Previous studies have shown that less differentiated neuroendocrine tumours, as determined by a higher Ki-67 index, are more likely to show higher uptake of 18F-FDG on PET, while showing lower uptake on imaging, which specifically shows neuroendocrine tumours, such as SRS.9,15,19 Theoretically, lesions on 18F-FDG PET might also be due to de-differentiation of secondary lesions which, were initially a well­differentiated carcinoid. However, the 18F-FDG PET-positive lesions in our patients were not previously seen, for example on 18F-DOPA PET, which should have been the case if they were indeed initially a well-differentiated carcinoid. Secondly, to our knowledge, no studies exist describing dedifferentiation of carcinoid tumors. In this study we did not take biopsies of all metastatic lesions to rule out the possibility of a false negative 18F­FDG PET scan, as cytological and histological verification runs a risk of bleeding complications in the highly vascular carcinoid lesions. While this risk has certainly to be accepted for establishing an initial diagnosis, during the course of the disease in case of several metastatic lesions using the combination of PET tracers can be extremely helpful. Especially considering the excellent sensitivities of the PET techniques and the fact that no new or rapidly growing lesions have been discovered so far, the chance of a false negative 18F-FDG PET scan seems small. The possibility of distinguishing lesions without the need of taking biopsies with the associated risks is the great advantage of the combined use of these two radiotracers. In conclusion, the difference in uptake between 18F-FDG and 18F­DOP A in tumour lesions can be used to make the distinction between metastases from the carcinoid tumour or the SPM. This may clearly have therapeutic consequences, allowing curative treatment for non­metastasised SPMs, even in case of metastatic carcinoid disease. 
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ABSTRACT Positron emission tomography (PET) using 6-[F-18]fluoro-L­dihydroxyphenylalanine (18F-DOPA) has an excellent sensitivity to detect carcinoid tumor lesions. 18F-DOP A-tumor uptake and the levels of biochemical tumor markers are mediated by tumor endocrine metabolic activity. Therefore we evaluated whether total 18F-DOPA-tumor uptake on PET, defined as the whole-body metabolic burden (WBMTB) reflects tumor load per patient, as measured with tumor markers. Methods 77 consecutive carcinoid patients who underwent a 18F-DOP A PET scan in two previously published studies were analyzed. For all tumor lesions mean standardized uptake values (SUVs) at 40% of the maximal SUV and tumor volume on 18F-DOPA PET were determined and multiplied to calculate a metabolic burden per lesion. WBMTB was the sum of the metabolic burden of all individual lesions per patient. As tumor markers served 24-hour urinary serotonin, urine and plasma 5-hydroxindole acetic acid (SHIAA); catecholamines (nor)epinephrine, dopamine and their metabolites, measured in urine and plasma, and serum chromogranin A. Results All but one were evaluable for WBMTB, 74 patients had metastatic disease. 18F-DOPA PET detected 979 lesions. SUVmax on 18F-DOPA PET varied up to 29-fold between individual lesions within the same patients. WBMTB correlated with urinary serotonin (r = 0.68) and urinary and plasma SHIAA (r = 0.78 and 0.66). WBMTB also correlated with urinary norepinephrine, epinephrine, dopamine and plasma dopamine, but not with serum chromogranin A. - 108 -
18F-DOP A PET reflects metabolism in carcinoid 
Conclusion Tumor load per patient measured with 18F-DOP A PET correlates with tumor markers of the serotonin and catecholamine pathway in urine and plasma in carcinoid patients and reflects metabolic tumor activity. 
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Chapter 6 INTRODUCTION Carcinoids are rare tumors arising from neuroendocrine cells, which can produce and secrete a variety of biochemical markers, including serotonin and 5-hydroxindole acetic acid (5-HIAA), the main metabolite of serotonin. Carcinoid tumors can produce several other markers including catecholamines in 48% of patients.1-3 Measuring urinary 5-HIAA excretion is currently the cornerstone in the diagnosis and response evaluation of metastatic carcinoid tumors, in combination with data provided by computer tomography (CT) and magnetic resonance imaging (MRI).4 Recently, it has been suggested that serum chromogranin A is a better marker than urinary 5-HIAA excretion for follow-up of carcinoid patients.5, 
6 The disadvantage of urinary 5-HIAA is that the collection of 24-hour urine samples can be unrealiable and is inconvenient for the patient.7 Therefore a more convenient and accurate marker is of interest. But in contrast to 5-HIAA, serum chromogranin A does not reflect the metabolic status of these tumors.6, 8 The intrinsic property of neuroendocrine tumor cells to take up and decarboxylate amine precursors, which is reflected in the secretory activity of these tumors, is also used for positron emission tomography (PET) imaging of these tumors. PET using the catecholamine precursor 6-[F-18]fluoro-L-dihydroxyphenylalanine (18F-DOPA) has an excellent sensitivity to detect carcinoid tumor lesions.9-11 In the intracellular accumulation of 18F-DOP A by neuroendocrine tumors several essential steps play a role. 18F-DOPA is transported into the cell by the L-type amino acid transporter (LAT) and then decarboxylated by aromatic-L-amino acid decarboxylase (AADC), resulting in the formation of 18F-dopamine. This is subsequently transported into specific storage vesicles by vesicular monoamine transporter and protected from enzymatic degradation. Unstored 18F-dopamine is subject to degradation in the cytosol and the - 110 -
18F-DOP A PET reflects metabolism in carcinoid formed metabolites leave the cell via diffusion.12 The increased demand for precursors by the overactive secretory pathways in carcinoid tumors induces high 18F-DOPA-uptake in tumor cells. 13, 14 Currently, functional information of PET is increasingly being incorporated into staging and follow-up. This information complements the anatomical information, such as exact size and location of lesions, provided by CT and MRl.15-18 Whether 18F-DOPA-PET can also complement biochemical tumor makers or become a surrogate marker is as yet unknown. Attempts to quantitate metabolic disease activity are usually based on the maximum standardized uptake value (SUVmax) and the mean standardized uptake value (SUVmean) within a certain volume of interest (VOI). PET imaging additionally opens ways to analyze whole-body metabolic tumor burden (WBMTB) as quantitative measure of the overall tumor load. This approach was used with 18F-FDG PET in non-Hodgkin's lymphoma to measure the treatment response after chemotherapy with glucose uptake in the tumor. With PET WBMTB was the best measure of overall response when compared with SUVmax and SUVmean.19 In order to study whether the metabolic endocrine tumor activity measured by biochemical markers in plasma and urine correlates with metabolic activity, as measured on 18F-DOP A PET, the aim of the present study was to evaluate in a group of patients who underwent 18F-DOPA PET as well as careful collection of relevant biochemical tumor markers whether total 18F-DOP A-tumor uptake on PET, reflects the tumor load per patient, as measured with the tumor markers. - 111 -
Chapter 6 PATIENTS AND METHODS 
Patients For this study we selected all consecutive patients with a carcinoid tumor (n=77) who underwent 18F-DOP A PET as well as a careful collection of relevant biochemical tumor markers in two previously published 18F­DOP A PET studies of our institute (between October 2003 and February 2007).9, 10 The inclusion criteria for these studies were patients with a strong suspicion of a carcinoid tumor, based on clinical and biochemical findings, and patients with histopathologically proven carcinoid tumor, with a clinical indication for (re)staging. All patients had to have at least one abnormal lesion on conventional imaging. These previous studies were designed to evaluate the diagnostic sensitivity of 18F-DOPA PET and 11C-5-hydroxytryptophan (1 1C-5-HTP) PET in patients with carcinoid tumors. Extended biochemical analyses were performed and charts were checked for the presence of somatostatin analogue treatment. The studies were approved by the medical ethical committee, all patients gave informed consent. 
18F-DOPA PET 
18F-DOP A was locally produced and performed as described earlier.9, 10, 20 In short, whole body 2D-PET images were acquired 60 min after the intravenous administration of 18F-DOPA (180 ± 50 MBq). The patients fasted for 6 h before the examination and were allowed to continue all medication. For the reduction of tracer decarboxylation and subsequent renal clearance and to increase tracer uptake in tumor cells all patients received 2 mg/kg carbidopa orally as pre-treatment 1 h prior to the 18F­DOP A injection.21-23 - 112 
18F-DOP A PET reflects metabolism in carcinoid Image analysis The 18F-DOP A PET scans were reviewed. For each patient, a WBMTB was determined as the sum of the metabolic burden (MB) of each tumor lesion in the PET image.19 In order to make the MB independent of body weight and injected dose the SUV was used, which is defined as: SUV = activity concentration [MBq/ml] / injected dose per gram [MBq/g] In turn, the MB was calculated as: MB = SUVmean x volume of tumor lesion. Both SUVmean and tumor volume were obtained from the PET image using a VOi that was defined as the tumor volume enclosed by a 40% isodensity surface.24, 25 This VOi was semi-automatically drawn. First, the tumor was fully enclosed by a hand-drawn ellipsoid. In this pre­selected volume the maximum SUV was established. Finally, the VOi contained all voxels with values over 40% of the maximum. Biochemical analysis Tumor markers measured for serotonin metabolism were serotonin levels in a 24-h urine collection, urinary and plasma 5-HIAA levels.26 As markers for catecholamine metabolism we determined urinary and plasma concentrations of adrenalin, noradrenalin and dopamine, and urinary concentrations of the major catecholamine metabolites homovanillic acid (HV A), 3,4-dihydroxyphenylacetic acid (DOPAC), vanillylmandelic acid (VMA), vanillic acid (VA), 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) metanephrine, normetanephrine and 3-methoxytyramine (3-MT) in a 24-h urine collection.27-29 Serum chromogranin A was determined using a radioimmunoassay (Cga-React, Cis Bio International, Gif-sur-Yvette, France) as a marker for general neuroendocrine tumor activity (reference interval 20-100 mg/L). All laboratory analyses were performed within 3 months of the 18F-DOP A PET scan in the original studies. 9, 10 - 113 -
Chapter 6 Statistical analysis For correlations between WBMTB and biochemical data, Spearman' s r test was calculated. Significance level was 0.05, two-sided. The statistical tests were carried out using the SPSS package version 14.0. RESULTS Seventy-four patients had metastatic disease. In 76 of 77 carcinoid patients the tumor volume with 18F-DOPA PET generated by the computer using the SUVmean seemed to correlate well with the visual tumor volume (Figure 1). In one patient visual inspection of the computer generated tumor volume showed a gross underestimation of the visually identified tumor volume due to enormously heterogeneous uptake in the metastases. This patient had an extremely large tumor load in the liver and upper abdomen, consisting of confluent lesions with varying uptake­intensities in different parts of the tumor. As a result, the less avid lesions, which had uptake-values below the 40% threshold of the SUVmax of the hottest lesion, were not included in the lesion volume by the computer algorithm. Therefore, this patient was excluded from further analysis. 
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• 
• 
-Figure 1. Example of a 18F-DOP A PET scan of a patient with a semi-automatically generated volume of interest (VOI) of a carcinoid lesion. A total of 979 lesions were detected by 18F-DOPA PET (Table 1). 18F­DOP A PET tumor uptake was shown to vary greatly between carcinoid lesions within individual patients. Within patients SUV s of different lesions showed a large variance; this range was wider for SUVmax than for SUVmean, as the former is more sensitive to outliers. Median difference between the SUVmax of different lesions within one patient of 11.6 (range 0.1-28.7) and the SUVmean of 7.2 (0.2-19.7) (Figure 2). 
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Chapter 6 Table 1. Patient and lesion characteristics 
Number of evaluable patients 76 
New patients vs. patients with known disease (N of patients) 30/46 
Somatostatin analogue treatment (N of patients) 28 
Interferon treatment (N of patients) 2 
Number of 18F-DOP A PET positive lesions 979 
Median number per patient (range) 12 (0-85) 
SUVmax, median (range) 3.9 (0.8-33.4) 
SUVmean, median (range) 2.6 (0.5-22.7) 
Volume in cm3, median (range) 7.6 (0.55-2308) 
WBMTB in cm3, range 712 (0-19,000) 
30 
C: · •• : :E • 
"i • 
> - 20 • • • • 
::J 5i • • •• • • • • • en :;; • • • • • C: C'CS • •• • • • ·- C. • • • • • • •  Cl) Cl) ... ,. . . -:..• (.) 5 10  C: • • . . � . . Cl) • • • • • ... ••• ••• 
� • • . . ,:.; . . · · ·-· · · i5 . , .. . . . ,·,..:: 1 
SUVmax SUVmean Figure 2. Difference between highest and lowest SUVmax and SUVmean within 
individual patients, each dot representing one patient. Horizontal bars represent 
the median values. 
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•• • ••••••• ••• • Figure 3. Distribution of whole-body metabolic burden for all individual patients (n=76), each dot representing one patient. Urinary serotonin and/or 5-HIAA levels were elevated in 64 patients (84%). WBMTB showed significant correlations with both urinary serotonin and its metabolite 5-HIAA in urine and plasma (Table 2). The strongest correlation was found between WBMTB and 24-hour urinary 5-HIAA. There was no difference in strength of correlations between newly diagnosed patients and patients during follow-up. Elevated levels of catecholamines and/or their metabolites were found in 35 patients (46%). The single most frequently elevated marker was 3-MT, which was elevated in 17 patients (22%). We found significant correlations between WBMTB and the urinary levels of the three main catecholamines norepinephrine, epinephrine and dopamine (Table 2). - 117 -
Chapter 6 There was no difference between newly diagnosed patients and patients known with a carcinoid tumor. Serum levels of chromogranin A did not correlate with WBMTB (P = 0.14). Levels of the three major catecholamines norepinephrine, epinephrine and dopamine in 24-hour urine were significantly correlated with urinary 5-HIAA and serotonin levels (data not shown). 
Table 2. Significant correlations between biochemical 
markers and 18F-DOPA PET in total group. 
Correlation Variance explained 
coefficient by correlation 
Urinary serotonin 0.59 0.35 
Urinary 5-HIAA 0.78 0.61 
Plasma 5-HIAA 0.66 0.44 
Urinary norepinephrine 0.53 0.28 
Urinary epinephrine 0.38 0.14 
Urinary dopamine 0.41 0.17 
Urinary 3-MT 0.44 0.19 
Plasma dopamine 0.39 0.15 DISCUSSION We demonstrated that whole-body metabolic tumor burden, as measured with 18F-DOP A-tumor uptake on PET, correlates with biochemical tumor markers in patients with a carcinoid tumor, thus reflecting metabolic endocrine tumor activity. Tracer uptake correlated with urinary and plasma markers of both the serotonin and the -118 -
18F-DOP A PET reflects metabolism in carcinoid catecholamine pathway, and presented a whole-body image of the specific sites where endocrine production is occurring. 18F-DOP A PET tumor uptake was shown to vary greatly between carcinoid lesions within individual patients, up to 29-fold differences between individual lesions were observed. In addition, there was also great inter-patient variance. The strongest correlation was found between WBMTB and urinary 5-HIAA levels. This is interesting considering the fact that urinary 5-HIAA is the most widely used marker for follow-up and response assessment of carcinoid tumors. Currently, there is some debate about the optimal tumor marker for follow-up and management of patients with a carcinoid tumor. Serum chromogranin A has been suggested to replace urinary 5-HIAA. s, 6 Chromogranin A plays an important role in the regulation of storage and secretion of hormones and peptides. It is localized in the secretory granules of most neuroendocrine cells.3° Chromogranin A was shown to correlate with tumor load in patients with carcinoid tumors.31, 32 Here we show that chromogranin A does not reflect the metabolic activity of these tumors, since the whole-body metabolic tumor activity on 18F-DOPA PET did correlate with carefully collected urinary 5-HIAA but not with serum chromogranin A. As WBMTB is the product of tumor volume x metabolic tumor activitity, and chromogranin A is known to correlate with tumor burden, it follows that it does not correlate with metabolic tumor activity. This is in accordance with previous studies which show that chromogranin A fails to reflect the metabolic activity of carcinoid tumors.6, 8 Our study provided a controlled setting in which a careful collection of all biochemical markers was performed. For routine follow-up reliable urinary 5-HIAA measurements to determine metabolic tumor activity are more difficult to obtain. In view of this an automatically generated WBMTB may prove an interesting marker, since it has demonstrated a good correlation with the metabolic activity of the carcinoid tumor. The additional advantage is that it is a one-stop diagnostic modality where excellent tumor localization and - 119 
Chapter 6 information about the metabolic tumor activity are both obtained with one scan. In our patients we found a correlation between WBMTB and catecholamine markers, but these correlations were weaker than those found between WBMTB and serotonin markers. About half of our patients had elevated catecholamine levels, which is conform the numbers found in literature.1-3 This is less than the 84% of patients who had elevated serotonin or 5-HIAA. Intrinsic tumor catecholamine production explains at least partly the elevated catecholamine levels in these patients. In about two-thirds of carcinoid tumors at least one of the enzymes necessary for catecholamine synthesis is present.2 These enzymes are focally distributed within the tumor, indicating that a small subpopulation of carcinoid cells could be responsible for the catecholamine synthesis in these patients.2 Catecholamine levels can also be influenced by sympathoadrenal activation and medication, which could provide an alternative explanation for elevated catecholamine levels in these patients. These influences affect catecholamines proportionally much stronger than their metabolites.33 Several factors can influence SUV s, thereby influencing the strength of the correlation between tumor uptake and biochemical markers. Firstly, the time after injection is an important variable that can influence SUVs. A previous study on 18F-DOPA PET in carcinoid tumors found that SUVs did not differ when measured after either 30 or 90 minutes, indicating that a plateau phase is already reached at 30 minutes.34 This was confirmed in other 18F-DOP A PET studies, which showed that most tumor uptake occurred in the first 30 minutes and that uptake then remained constant for at least 10 0 minutes.35-37 Thus, SUVs measured after 60 minutes, as was done in our study, render adequate and reliable measures of tumor tracer uptake. A second factor is the amount of available tracer. Pre-treatment with carbidopa, a peripheral inhibitor of AADC is known to improve image quality for 18F-DOP A PET due to higher tumor-to-background ratios. Carbidopa further improves lesion detection through increased SUV values 
- 120 
18F-DOP A PET reflects metabolism in carcinoid of lesions.21-23, 35 The fact that 18F-DOPA uptake is visible in other structures in our scans serves as a visual control for sufficient tracer availability, otherwise most 18F-DOP A would go to the tumor, as this is the most active tissue. In conclusion, total tumor load per patient defined as whole-body metabolic tumor burden measured with 18F-DOPA PET correlates with biochemical markers, reflecting metabolic tumor activity in carcinoid patients. It is a one-stop diagnostic tool, providing both a measure of the metabolic tumor activity and a whole-body overview of the specific sites where endocrine production is occurring. In future, WBMTB could serve as alternative assessment parameter to evaluate disease extent and biochemical activity in carcinoid patients. Future studies should investigate the use of this new parameter for follow-up or for the assessment of treatment response. - 121 -
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Table 1. Characteristics of the patients, previous therapy, and biochemical response to everolimus Patient Sex, Previous therapy Insulin in mE/L / proinsulin in pmol/L (elevation above Tumor response and Age (years) 
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Chapter 7 Serum insulin was determined with a DSL-160 0 insulin radio­immunoassay (upper level of normal 16.9 mU/L) (Beckman Coulter; Brea, CA) and intact proinsulin (upper level of normal 7.3 pmol/L) as described previously.5 The patients underwent computer tomography (CT) scanning before start of treatment, after 2 months and 3 monthly thereafter to determine tumor response according to RECIST 1.1.6 18F-FDG-PET was performed at the same time points plus at 2 and 5 weeks. The 18F-FDG­uptake was quantitated as the maximum standardized uptake value (SUVmax) in regions of interest.7 To quantify glucose-uptake in tumor and normal tissues SUVmax values were calculated for the three hottest tumor lesions, the myocardium, and forearm muscles. After start of everolimus clinical condition and self-reported well­being improved in all patients. Before everolimus therapy during hypoglycemic episodes, insulin levels were 2.5-6.3-fold elevated compared to the upper limit of normal and proinsulin levels 35-45-fold (Table 1). Glucose levels normalized already on day 4, 8, and 14 respectively (Figure 1) and the continuous glucose infusions could be discontinued. In the heavily pre-treated patient this effect subsided after 13 weeks and was temporarily restored by increasing the octreotide dose to 20 0 µg three times daily. Insulin levels were lower but still elevated in all after 4 weeks (Figure 1, Table 1). This reduction further persisted in two patients, but increased again in patient 3 after 5 weeks. 
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Everolimus for insulinomas All patients experienced stable disease for respectively 5, 8, and 8+ months. Figure 2 shows the changes in tumor size per patient. 18F-FDG-PET visualized the tumor lesion in the pancreas and more liver lesions than CT in all patients (Figure 3). Figure 2. Waterfall plot showing the percentage response in size and maximum standardized uptake values respectively after 5 months per patient on CT (white bars) and 18F-FDG-PET (black bars). ) .  Bars from left to right patient 1 to 3. 




pretreatment 2 weeks 5 weeks 5 months 
B C Figure 3. Patient 1. A. 18F-FDG-PET scans. Pathological uptake in the liver lesions 
and physiological uptake in the muscles and myocardium decreases during 
treatment with everolimus. B. Pre-treatment CT scan showing a pancreatic mass 
and multiple liver lesions. C. Fusion of the pre-treatment CT and 18F-FDG-PET 
confirming uptake in the pancreatic and liver lesions. 
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15  20 Figure 4. Maximum standardized uptake values decrease on the repeated 18F-FDG­
PET scans. Physiological uptake in the myocardium (•) and forearm (◊) is 
averaged for all patients and uptake in the hottest three tumor lesions is averaged 
per patient. Patient 1 (■), patient 2 (•), patient 3 (T). 
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Everolimus for insulinomas Earlier studies with everolimus in mixed islet cell tumors reported mainly stable disease (60-80%) and partial responses (4-27%).2,3 In insulinoma patients treated with everolimus two experienced stable disease and two a partial response.4 The small effect on tumor size in our patients reflects these results. Also other treatment options for malignant insulinoma often have a limited effect on tumor size.8-11  Regretfully these studies do not describe the swiftness of hypoglycemia control. Despite the limited effect on tumor size, rapid glucose normalization was observed in our insulinoma patients when everolimus was initiated. First this will be due to the observed decreased (pro )insulin secretion, although (pro )insulin levels remained elevated. Therefore, besides the lower (pro )insulin levels, an additional factor must be responsible for the glucose normalization. We saw an avid 18F-FDG-uptake before treatment in tumor lesions and muscles in our patients. This increased muscle uptake was also seen in euglycemic hyperinsulinemic clamping studies, in which insulin administration resulted in increased muscular uptake.12 In our patients everolimus induced a significant reduction in 18F-FDG-tumor uptake. This was also observed in lesions of patients with non-small cell lung cancer lesions treated with everolimus.13 However in our insulinoma patients there was in addition a striking reduction in 18F-FDG-muscle uptake. This points to a general metabolic effect of everolimus. We consider downregulation of glucose transporter 1 (GLUTl) in tumor as well as normal tissues by everolimus14 the second reason for glucose normalization. GLUTl regulates the cellular uptake of glucose in insulin-stimulated tissues.15 In vitro prolonged mTOR-inhibitor treatment leads to Akt-inhibition by reduced mTOR complex 2 (mTORC2)­formation.16 As a consequence of the declined Akt-phosphorylation, transcription and translation of GLUTl to the plasma membrane is reduced as shown in vitro for adipocytes, fibroblasts and in xenograft tumor models.14,17 In a xenograft pancreatic cancer model GLUTl-reduction during mTOR-inhibition coincided with a reduction in 18F-FDG-uptake in 
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Chapter 7 the xenograft.17 GLUTl-reduction leads to a lower glucose transport into the cells and rising plasma glucose levels resulting in peripheral insulin resistance.18-20 This phenomenon is also described in cancer patients and transplant patients on mTOR-inhibitors.2,20-22 Nine percent of the neuroendocrine patients experienced plasma glucose levels above 13.9 mmol/L2, in renal transplant patients this was 5.9%.23 This difference reflects the higher everolimus doses administered to the cancer patients. However even in renal transplant patients treated with the mTOR-inhibitor sirolimus the oral glucose tolerance test showed already a 30% increase in incidence of impaired glucose tolerance.20 In conclusion, the effect of everolimus on glycemic control in metastatic insulinoma patients is not only the consequence of a decrease of (pro )insulin levels and anatomical anti-tumor effects but also due to peripheral glucose resistance pointing to on and off targets effects of everolimus. -134 -
Everolimus for insulinomas REFERENCES 1 .  Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010;28:245-255 2. Yao J, Phan A, Chang D, et al. Efficacy of RAD00l (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-4318 3. Yao J, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 2010;28:69-76 4. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009;360:195-197 5. Ruige JB, Dekker JM, Nijpels G, et al. Hyperproinsulinaemia in impaired glucose tolerance is associated with a delayed insulin response to glucose. Diabetologia 1999;42:177-180 6. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1 .1) . Eur J Cancer 2009;45:228-247 7. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004;45:1431-1434 8. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet­cell carcinoma. N Engl J Med 1992;326:519-523 9. Eriksson B, Oberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993;32:203-208 10. K wekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oneal 2008;26:2124-2130 11 .  Kulke M, Lenz H, Meropol N, et al. Activity of  sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-3410 12. Roy F, Beaulieu S, Boucher L, et al. Impact of intravenous insulin on 18F­FDG PET in diabetic cancer patients. J Nucl Med 2009;50:178-183 
- 135 -
Chapter 7 13. Nogova L, Boellaard R, Kobe C, et al. Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. J Nucl Med 2009;50:1815-1819 14. Taha C, Liu Z, Jin J, et al. Opposite translational control of GLUTl and GLUT4 glucose transporter mRNAs in response to insulin. J Biol Chem 1999 ;27 4:33085-33091 15. Sargeant RJ, Paquet MR. Effect of insulin on the rates of synthesis and degradation of GLUTl and GLUT4 glucose transporters in 3T3-Ll adipocytes. Biochem J 1993;290:913-919 16. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101 17. Ma W, Jacene H, Song D, et al. [18F]Fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 2009;27:2697-2704 18. Di Paolo S, Teutonico A, Leogrande D, et al. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol 2006;17:2236-2244 19. Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTOR inhibition by rapamycin prevents beta cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008;57:945-957 20. Teutonico A, Schena P, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16:3128-3135 21. Motzer R, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456 22. Yee K, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD0Ol) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006;12:5165-5173 23. Araki M, Flechner S, Ismail H, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006;81 :335-341 
- 136 -
Chapter 8 Deficiencies in fat-soluble vitamins in long­term somatostatin analogue users Helle-Brit Fiebrich1, Gerrit van den Berg2, Ido P. Kema3, Thera P. Links2, Jan H. Kleibeuker4, Andre van Beek2, Annemiek M.E. Walenkamp1, Wim J. Sluiter3, Elisabeth G.E. de Vries 1 Departments of 1Medical Oncology, 2Endocrinology, 3Laboratory Medicine, 4Gastroenterology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands Submitted 
Chapter 8 ABSTRACT Background & Aims Somatostatin analogues are administered to control amine and peptide hypersecretion in acromegaly and carcinoid patients. Somatostatin analogues reduce bowel uptake of fat, frequently resulting in steatorrhea. Increased fat in the stools can lead to loss of fat-soluble vitamins. The effect of long-term somatostatin analogue use on vitamin levels is unknown. Therefore we investigated the frequency and severity of fat-soluble vitamin deficiencies in long-term somatostatin analogue users. Methods All patients with acromegaly or carcinoid tumors using somatostatin analogues for � 18 months visiting the UMCG, between December 2008 and April 2009 were eligible. Clinical and laboratory parameters, length and dose of treatment, vitamin or pancreatic enzyme suppletion, stool frequency and previous intestinal resection were collected. Results 54 patients were included (19 with acromegaly, 35 with carcinoid disease). Twelve patients experienced steatorrhea, two carcinoid patients complained of night blindness. Forty-two (78%) were deficient for one or more vitamins, 32% (n = 17) for multiple. Deficiencies for vitamin A, D, E, Kl and E in erythrocytes occurred in respectively 6%, 28%, 15%, 63% and 58% of the patients. Elevated parathyroid hormone was seen in 14 patients, lengthened prothrombin time in three. - 138 
Fat-soluble vitamins and somatostatin analogues Frequency and severity of vitamin D, E and Kl deficiencies were similar in both patients groups. Treatment duration did not influence vitamin levels. Length of intestinal resection and age correlated negatively with vitamin A levels. 
Conclusions Deficiencies of fat-soluble vitamins are frequent during long-term somatostatin analogue treatment. Therefore, fat-soluble vitamins should be monitored and deficiencies supplemented in these patients. - 139 -
Chapter 8 INTRODUCTION Long-term somatostatin analogue therapy is important to control symptoms of hypersecretion of biologically active amines and peptides in diseases such as acromegaly or metastatic carcinoid tumors. Other indications for long-term use include certain pancreatic islet cell tumors and the dumping syndrome. Side effects of somatostatin analogue treatment are usually acceptable and often passing. The most common adverse effects are diarrhea, abdominal discomfort and nausea. Gallstones, usually asymptomatic, occur in 10-50% of the treated patients.1-3 Steatorrhea is an adverse effect experienced by up to 29% of patients on somatostatin analogue treatment.4 When patients with acromegaly or a carcinoid tumor cannot be cured by complete surgical tumor resection, they often require long-term somatostin analogue treatment for symptom control. Two somatostatin analogues are currently available for clinical use. Octreotide is registered since 1989, and lanreotide in the Netherlands since 1999. With the passing of time, numerous patients have now received a significantly long-term treatment with these drugs. Given the fat loss in the stool following somatostatin treatment, this will go together with loss of fat-soluble vitamins A, D, E and Kl in the stool. A likely risk factor is the duration of somatostatin analogue treatment. Studies performed thusfar have investigated patients after a relative short treatment period and may therefore well underestimate the frequency of vitamin deficiencies during long-term somatostatin analogue treatment. The only evidence pointing towards an increased risk of a deficiency of fat-soluble vitamins in patients receiving long-term somatostatin analogue treatment comes from a study in acromegaly patients. In this study 103 patients were treated for 3-30 months with a mean duration 24 months. They reported a slight but significant fall of carotene, although values remained in the normal range. In addition, one patient in their study developed a prolonged prothrombin - 140 
Fat-soluble vitamins and somatostatin analogues time (PT), which resolved after vitamin K suppletion.5 Others observed no changes in serum carotene, vitamin D, or vitamin K in eight acromegaly patients who were on octreotide for four months. 6 The frequent resection of a part of the small intestine, as performed in midgut carcinoid patients, could be an additional reason for malabsorption. The severity of the malabsorption after an intestinal resection depends on the total of digestive surface area and the portion of small intestine remaining.7 Carcinoid patients, that have undergone a partial small bowel resection, may therefore be at greater risk to develop vitamin deficiency than carcinoid or acromegaly patients without a bowel resection. No previous study has systematically investigated long-term somatostatin users and has done so for levels of the complete set of fat­soluble vitamins. Therefore, the extent and severity of fat-soluble vitamin deficiency in patients with acromegaly or a carcinoid tumor are unknown. This study aims to determine the frequency and severity of fat-soluble vitamin deficiency in these patients with a treatment duration of at least 18 months. 
MATERIALS AND METHODS Patients Patients eligible for this cross-sectional study visited the UMCG between December 2008 and April 2009 for acromegaly or a metastasized midgut carcinoid tumor and were treated with a somatostatin analogue for more than 18 months. Patient inclusion was limited to the winter months in order to rule out seasonal influences on vitamin levels (especially vitamin D) as an explanation for variation of vitamin levels between patients. Patients younger than 18 years and those unable to give informed consent were excluded. Patient charts were checked for diagnosis, reports of previous intestinal resection and length of resection, dose and length of - 141 -
Chapter 8 treatment with somatostatin analogues and possible signs and symptoms of a deficiency of fat-soluble vitamins. In addition, patients were asked if they took vitamin supplements, whether they experienced steatorrhea ( defined as loose, greasy stools that are difficult to flush), had special eating habits and if they had complaints that could be due to a vitamin deficiency, such as night blindness or an increased propensity for bleeding. The study was approved by the local medical ethics committee and all patients gave written informed consent. The study was registered at the Nederlands (Dutch) trial register (registry), trial code 1730 . Biochemical Analysis To estimate the extent of side effects of somatostatin analogues on the uptake of fat-soluble vitamins we determined plasma concentrations of the fat-soluble vitamins A (retinal), D, E, Kl as described earlier.8-11 Vitamin E was also measured in the membrane of erythrocytes with an HPLC method, as vitamin E levels in erythrocytes provide a better measure of long-term vitamin E status than plasma levels.12,13 After liquid/liquid extraction with hexane, using tocol and retinol acetate as internal standards, a 35 µL sample was injected on a Waters Symmetry C18 column (Waters Corporation, Milford, MA) and analysed, using a ASI-10 0 autosampler (Dionex, Sunneyvale, CA), a P680 HPLC pump (Dionex, Sunneyvale, CA) and a Thermo-Finnigan PDA (photodiode array) detector (Thermo Fisher Scientific Inc., Waltham, MA). ATLAS Chromatography Data System (Thermo Fisher Scientific Inc., Waltham, MA) was used for recording and calculating the results. Lower limits of normal in plasma were 0 .8 µmol/L for vitamin A, 50 nmol/L for vitamin D14, 19.2 µmol/L for vitamin E and 0 .8 nmol/L for vitamin Kl. Lower limits of normal for vitamin E in erythrocytes was 4.58 µmol per 10 13 erythrocytes. Reference interval verification, performed in 25 samples of healthy individuals using the EP Evaluator software package release 8 (Data Innovations Inc., South -142 -
Fat-soluble vitamins and somatostatin analogues Burlington, VT), confirmed that the values used in our center for vitamin A and E were correct.15 To measure effects of a possible fat-soluble vitamin deficiency, vitamin-dependent parameters were included. For vitamin D parathyroid hormone (PTH) was measured, while for vitamin Kl, PT and activated partial thromboplastin time (aPTT) were evaluated. Statistical Analysis As control values for healthy individuals served the normal values and the 95% confidence interval as used by our laboratory. In a sample size of 19 acromegaly patients we can demonstrate a significant difference between vitamin levels if 3 abnormal values are measured (15% ). In 35 carcinoid patients it is possible to show a significant difference between vitamin levels if 4 abnormal values are measured (12%). The chi-square test was used to test for differences between patients and normal values and the Mann-Whitney U test to test for differences between groups of carcinoid and acromegaly patients. In a linear univariate regression analysis age, sex, length of treatment, treatment dose, type of somatostatin analogue, presence of steatorrhea, pancreatic enzyme suppletion, diagnosis and bowel resection were tested for associations with plasma vitamin levels. For the analysis, bowel resection was divided into four categories based on the risk of developing malabsorption: no resection, less than 100 cm of bowel resected, between 100 and 200cm resected and more than 200 cm resected.16 Factors with a P level < 0.15 were tested in a multivariate regression analysis, using the reverse stepwise method. Significance level was 0.05, two-sided. Statistical tests were performed using the SPSS package version 16.0. - 143 -
Chapter 8 RESULTS Patient Characteristics A total of 56 patients were asked to participate, one carcinoid patient and one acromegaly patient declined participation. The remaining 54 patients were analyzed, 19 patients with acromegaly and 35 with a carcinoid tumor. Characteristics of these patients are shown in Table 1. Median length of somatostatin analogue treatment was 48 months (range 18-155), and did not differ between acromegaly and carcinoid patients (P = 0.18). Median dose of somatostatin analogue was 30 mg per 4 weeks for octreotide and 75 mg per 4 weeks for lanreotide. Median doses were the same for both patient groups. Of the carcinoid patients 25 had undergone a bowel resection in the past; in 23 less than 100 cm of bowel was resected, in one between 100 and 200 cm and in one more than 200 cm. Symptoms Two carcinoid patients experienced night blindness, which coincided with vitamin A deficiency. One patient was already referred to an ophthalmologist. Electroretinography demonstrated abnormalities typical for vitamin A deficiency in both patients. Oral suppletion of vitamin A resulted in a quick resolution of their symptoms. Twelve patients (n = 4 acromegaly patients and n = 8 carcinoid patients) complained about steatorrhea. Twelve carcinoid patients experienced increased stool frequency (range 1-10 times daily), but most had normal stools. An additional five carcinoid patients received suppletion of pancreatic enzymes for steatorrhea. Despite this suppletion all five patients had abnormal vitamin levels. Four patients ( one acromegaly patient and three carcinoid patients) took non-prescribed vitamin supplements (which included vitamins A, D and E), but three of these patients did show - 144 -
Table 1. Patient characteristics 
Total group Acromegaly Number of patients 54 19 Sex, male/female (N = 54) 27/27 1 1/8 Age in years, median (range) 60 (31-83) 56 (31-79) 
1---1 Octreotide/lanreotide (N = 54) 46/8 10/9 � 











Chapter 8 deficiencies for one (n = 2) or two (n = 1) of the fat-soluble vitamins. None of the patients had symptoms of increased bleeding tendency. Overall vitamin-deficiencies Abnormally low plasma levels for one or more fat-soluble vitamins were detected in 78% (n = 42). A deficiency of multiple vitamins was present in 32% (n = 17); in 26% (n = 14) of two, in 4% (n = 2) of three and in 2% (n = 1) of all fat-soluble vitamins. The three patients with a deficiency of three or four vitamins were all carcinoid patients. When vitamin E levels in erythrocytes, which reflects long-term vitamin E status, were considered for vitamin E status instead of plasma vitamin E levels more patients (n = 51, 91 %) had a deficiency. The most frequently deficient vitamin overall was vitamin Kl (n = 34, 63%). Low plasma levels of vitamin A were detected in 6%, of vitamin D in 28%, of vitamin E in 15% and low levels of vitamin E in erythrocytes in 58% of patients. The number of patients with a deficiency for vitamin D, E and Kl in plasma and for vitamin E in erythrocytes was significantly higher compared to what can be expected based on the normal values of our laboratory (P < 0 .0 01). This was not the case for vitamin A (P = 0 .15). Subgroup Analysis In the group of acromegaly patients 74% (n = 14) had abnormally low plasma levels for at least one vitamin and 47% for two vitamins. Based on vitamin E levels in erythrocytes, 89% had abnormally low levels for at least one vitamin. In this group all patients had normal levels of vitamin A. Vitamin D levels below 50 nmol/L were found in four acromegaly patients (21 % ). Lowered vitamin E plasma levels were present in three patients (16%), while vitamin Kl was deficient in 10 patients (53%). Vitamin E levels in erythrocytes were lowered in 14 (7 4 % ) . -146 -
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Carclnoid Figure 1. Scatter plots showing the range of plasma levels (unless otherwise noted) of the different fat-soluble vitamins per patient . Panel A. Vitamin A, Panel B. Vitamin D, Panel C. Vitamin E, Panel D. Vitamin E in erythrocytes Panel E. Vitamin K. Horizontal bars represent the median value, dotted lines the lower and upper limits of normal. - 147 -
Chapter 8 
Vitamin-dependent parameters In 60% of patients (n = 9) with vitamin D levels below 50 nmol/L PTH was elevated; these included 3 acromegaly patients and 6 patients with a carcinoid tumor. Four (12%) out of 34 patients with low vitamin Kl level, all with a carcinoid tumor, showed a prolonged PT, one patient also had a prolonged aPTT. This last patient was also on a vitamin K antagonist, which explains the prolonged PT and aPTT. 
Multivariate regression analysis Neither duration of treatment nor dose of either somatostatin analogue was associated with the plasma level of the various fat-soluble vitamins or vitamin E in erythrocyte levels. Increased stool frequency was not associated with lower vitamin levels in plasma or erythrocytes. Resection of a longer portion of small bowel showed an association with lower plasma vitamin A levels. In addition, higher vitamin A levels were negatively associated with older age. Plasma levels of vitamin D, E, K or levels of vitamin E in erythrocytes were not associated with any of the investigated factors. 
DISCUSSION This study shows that 78% of acromegaly and patients with metastasized midgut carcinoids who received a somatostatin analogue for longer than 18 months have deficiencies of one or more fat-soluble vitamins. This high level of vitamin deficiency was until now unknown. Two earlier studies addressing vitamin levels in patients treated with a somatostatin analogue5, 6 found a lowering of carotene, but values remained -148 -
Fat-soluble vitamins and somatostatin analogues in the normal range. The major difference of our study versus these studies is a median treatment duration which was much longer. Our study indicates that over the coming years vitamin deficiencies will be seen more frequently in the increasingly growing group of long­term somatostatin analogue users. Acromegaly patients precluded from surgical cure can receive long-term somatostatin analogue treatment.17 In addition, the life expectancy of patients with a metastasized carcinoid tumor has improved clearly during the last decades.18 Consequently, patients receive somatostatin analogues for extended periods. The most impressive symptom we observed was night blindness in two patients which showed a quick resolution of their complaints after vitamin A suppletion. Vitamin Kl was the most frequently observed deficient vitamin in our study. This deficiency resulted only in few patients in prolonged clotting times. However the plasma values indicate that these patients should be closely followed, in case of surgery vitamin Kl should be supplemented to prevent bleeding. In our study bowel resection also influenced plasma levels of vitamin A, but interestingly not to plasma levels of the other fat-soluble vitamins. Patients with a less than 200 cm residual bowel after resection run the highest risk to develop vitamin deficiencies. Both the guidelines of the British Society of Gastroenterology and of the American Gastroenterology Association Institute mention that fat-soluble vitamins may need to be supplemented if less than 200 cm of short bowel remains after resection, but do not suggest a specific screening regimen.16, 19 Early studies in small numbers of patients who had undergone resection of varying lengths of intestine showed that resection of more than 100 cm of the terminal ileum leads to insufficient intra-intestinal bile salt concentrations, which might in turn lead to fat and fat-soluble vitamin malabsorption.20, 21 However, for patients with a resection of more than 100 cm no regular monitoring of these vitamins is recommended by any of the existing guidelines. In our - 149 -
Chapter 8 study in only two carcinoid patients this was the case. In most carcinoid patients only short segments of the small bowel have been resected. Current guidelines of various national and international consensus groups for the treatment of acromegaly or carcinoid tumors do not recommend the monitoring of fecal fat excretion in patients treated with a somatostatin analogue.1,17, 22-26 Furthermore, only the guidelines by the European Neuroendocrine Tumor Society (ENETS) and of the Nordic neuroendocrine tumor group mention that pancreatic enzyme replacement can be given to alleviate steatorrhea. 22, 25 Deficiencies of fat-soluble vitamins may be less frequent in patients, who take pancreatic enzyme suppletion to improve fat uptake and uptake of fat-soluble vitamins and consequently steatorrhea. In our population five patients took such medication. These five patients did however still show deficiencies of the fat-soluble vitamins. Carcinoid patients may have another risk factor for the development of deficiencies of fat-soluble vitamins, as they frequently experience diarrhea as part of the carcinoid syndrome. Transit times in the small bowel and the colon are 2-6 times faster in carcinoid patients compared to healthy controls.27 A shorter transit time reduces the time available for the absorption of water and nutrients. Consequently, less fat is absorbed with shorter transit time.28 In that case fat-soluble vitamins will also be absorbed less. In our study no association between increased stool frequency and vitamin deficiency was found. We determined plasma vitamin E as well as vitamin E levels in erythrocytes. Plasma vitamin E half-life is subject to extensive interindividual variation because of the many factors that influence the turnover of the various lipoproteins.29 Vitamin E in erythrocytes, on the other hand, has a longer half life than vitamin E in plasma and therefore better reflects long-term vitamin E status.12, 13 Vitamin E in erythrocytes is located in the cell membrane where it is essential to prevent free radical damage to tissues and specifically to unsaturated lipids.30 Vitamin E levels in erythrocytes were deficient in 58% patients illustrating a clear effect on -150 -
Fat-soluble vitamins and somatostatin analogues long-term vitamin E status in these patients while plasma vitamin E levels was only lowered in 15%, likely due to recent dietary intake. Decreased vitamin levels can also be the consequence of insufficient dietary intake. We did not perform a detailed dietary history, but none of our patients reported an abnormal eating behavior. The four patients who reported to take non-prescribed vitamin supplements did still have vitamin deficiencies. Apparently, over-the-counter available vitamin supplements do not contain doses high enough to prevent fat-soluble vitamin deficiencies in these patients. In conclusion, deficiencies of fat-soluble vitamins in patients receiving long-term somatostatin analogue treatment are more frequent than previously known. Considering the possible consequences, we recommend routine assessment of fat-soluble vitamin status in these patients especially in patients with an intestinal resection, and in case of signs or symptoms. - 151 
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Chapter 9 Summary and Future perspectives 
Chapter 9 
SUMMARY Neuroendocrine tumors are a heterogeneous group of rare tumors, which arise from cells of the (neuro )endocrine system. These cells are located throughout the body and are capable of secreting biologically active amines, peptides and hormones. They can be divided into cell types that form localized glands (for example the adrenal medulla and the paraganglia) and cells that are dispersed throughout the entire body in other organs: the diffuse neuroendocrine system. Tumors originating from the chromaffin cells of the adrenal medulla are classified as pheochromocytoma, while tumors of the sympathetic and parasympathetic paraganglia are called paraganglioma. Neuroendocrine tumors that arise from the diffuse neuroendocrine system are mainly localized in the intestine, pancreas and lung, although they can originate in other organs as well. Intestinal neuroendocrine tumors are most commonly found in the small intestine, followed by the rectum and appendix. Neuroendocrine tumors that arise from the pancreas are called islet cell tumors. The World Health Organisation (WHO) categorizes neuroendocrine tumors based on histological features. The main categories defined by this classification system are well differentiated neuroendocrine tumors, well­differentiated neuroendocrine tumors of uncertain behavior, well­differentiated neuroendocrine carcinoma and poorly differentiated neuroendocrine carcinomas. In this thesis the term carcinoid tumor is used to describe the well-differentiated neuroendocrine tumor of the gastrointestinal tract. For tumor localization anatomical imaging, including computer tomography (CT), magnetic resonance imaging (MRI) or endoscopic ultrasound, in combination with nuclear functional imaging is performed, such as somatostatin receptor scintigraphy (SRS) using 111In-octreotide (for carcinoids and islet cell tumors) or scintigraphy with 123I-labeled meta-
- 156 -
Summary iodobenzylguanidine (for pheochromocytomas). Positron emission tomography (PET) using 6-[F-18]fluoro-L-dihydroxyphenylalanine (18F­DOPA) or 11C-5-hydroxytryptophan (11C-5-HTP) are based on the intrinsic property of neuroendocrine tumors to take up, decarboxylate, and store amine precursors. They have shown a superior performance compared to conventional imaging methods in patients with neuroendocrine tumors. Despite this, a clear overview of the relative performance of all currently available imaging methods, especially for islet cell tumors is missing. Indications to image vary, direct head to head comparisons are rare and most studies are performed in small patient numbers. Surgical excision is the only curative treatment option, but it can also be used in a palliative setting to prevent local problems and decrease hormone production. Also in case of metastatic disease median survival for well-differentiated neuroendocrine tumors is relatively long. Not only new imaging modalities but also new therapeutic options are currently being developed. New targeted drugs have shown promising results in patients with neuroendocrine tumors. The aim of this thesis was to address the diagnosis and management of patients with neuroendocrine tumors, focusing on carcinoid tumors, islet cell tumors and pheochromocytoma. In chapter 2 we present an overview of the literature on the anatomical and functional nuclear medicine techniques for the detection of islet cell tumors. A search was performed in the PubMed Medline and Embase databases of all English publications on imaging of islet cell tumors between 1995 and December 2009. When more than 5 studies were available for an imaging technique, only studies with more than 10 patients for that imaging technique were considered. Three indications can be distinguished for imaging of these tumors namely 1) tumor localization and staging of a patient with symptomatic pancreatic hormone hypersecretion, 2) a chance finding of a neuroendocrine tumor or its - 157 
Chapter 9 metastases and the subsequent search for a primary (pancreatic) tumor, and 3) screening in asymptomatic VHL and MENl-mutation carriers. Results of the clinical application of the different imaging methods are described per imaging indication and per tumor type. With Forest plots, the sensitivity of the different imaging techniques is presented. For the applicability of each imaging technique a level of evidence was assigned, based on the system of the Oxford Centre of Evidence Based Medicine. The level of evidence for all imaging indications and modalities was remarkably weak (2b at best). No separate sensitivities could be extracted for patients with a chance tumor finding, as these patients were always reported together with symptomatic patients. Moreover, the number of patients in most studies was very small. For tumor detection in patients with symptoms or a chance finding of neuroendocrine tumor anatomical imaging with ultrasound, CT and MRI has moderate sensitivities, although technical developments allow improvements. Endoscopic ultrasound and new metabolic PET imaging techniques achieve better results. Only a few studies have investigated the performance of imaging modalities for screening of mutation carriers. The best results are obtained with EUS, while CT and SRS showed moderate detection rates. US, MRI and PET have not been investigated. The aim of the study described in chapter 3 was to evaluate the sensitivity of 18F-DOPA PET in patients with proven catecholamine excess. Most studies until now included patients on the (suspected) presence of a pheochromocytoma or paraganglioma. In this study we address the issue from the even more basic clinical relevant question namely patients presenting with catecholamine excess. Currently, standard imaging in these patients consists of CT or MRI, usually in combination with 123I-MIBG scintigraphy. After the localization of the primary tumor, ruling out metastatic disease before initial surgery is important, since the detection of metastases affects treatment. Based on initial results in smaller studies 18F-- 158 -
Summary DOPA PET has emerged as an imaging technique with the potential to improve tumor detection and thus staging. In this study 18F-DOP A PET was therefore compared to conventional imaging with CT or MRI and 1231-MIBG scintigraphy. A total of 48 patients were studied. Analysis was performed on a patient and lesion-based level. Results of cytological, histological findings, all imaging tests, follow-up and biochemical data served as a composite reference standard. Metanephrines and 3-methoxytyramine were determined in plasma and urine. In addition, uptake of 18F-DOP A was measured with PET to determine the whole-body metabolic tumor burden and correlated with biochemical tumor markers. 
18F-DOPA PET showed tumor lesions in 43 patients, 1231-MIBG in 31 and CT /MRI in 32. The final diagnosis was pheochromocytoma in 40, adrenal hyperplasia in two, paraganglioma in two, ganglioneuroma in one and unknown in three. Patient-based sensitivity for 18F-DOPA PET, 1231-MIBG and CT/MRI was 90, 65 and 67%, respectively (P < 0.01 for 18F-DOPA PET versus both 1231-MIBG and versus CT/MRI, and P = 1.0 1231-MIBG versus CT /MRI). Lesion-based sensitivities were 73, 48 and 44 %, respectively (P < 0.001 for both 18F-DOPA PET versus 1231-MIBG and versus CT/MRI, P = 0.51 
1231-MIBG vs. CT/MRI). The combination of 18F-DOPA PET and CT/MRI was superior to 1231-MIBG and CT/MRI (93 vs. 76%, P < 0.001). Whole-body metabolic tumor burden measured with 18F-DOP A PET correlated with plasma free normetanephrine (r = 0.82), and urinary normetanephrine (r = 0.84), and metanephrine (r = 0.57). From the results of this study it was concluded that 18F-DOP A PET is superior to both 1231-MIBG scintigraphy and CT/MRI for the localization of tumors in patients presenting with catecholamine excess. Additional information provided by 18F-DOP A PET resulted in improved staging and influenced treatment decisions in 14 patients (29%). The combination of 18F­DOPA PET and CT/MRI was most informative in the diagnostic work-up. - 159 -
Chapter 9 This combination has the additional advantage that CT and MRI provide anatomical localization for the lesions visualized by 18F-DOP A PET. In chapter 4 we studied the value of 11C-5-HTP PET to detect previously unknown cardiac metastases in patients with a metastasized islet cell tumor. We were alerted that cardiac metastases might be more frequent than previously reported by the chance discovery by a patient with an islet cell tumor that showed cardiac metastases on 11C-5-HTP PET. 
11C-5-HTP PET is currently is the most sensitive imaging technique to visualize islet cell tumors. We therefore decided to re-analyze all patients with metastasized islet cell tumors who underwent as part of clinical trials an 11C-5-HTP PET scan with regard to myocardial metastases. From a database of all 11C-5-HTP PET scans performed in the University Medical Center Groningen all patients with a metastasized islet cell tumor that had received a 11C-5-HTP PET scan were selected. A group of 26 patients was available for analysis. Five patients (19%) had one or more lesion suspect for cardiac metastases on 1 1 C-5-HTP PET. No patient showed clinical signs or symptoms of cardiac involvement. In one patient the cardiac lesion was also discernible on CT after fusion with the 11C-5-HTP PET scan. Unfortunately, the available chest-CT scans, not designed to detect cardiac metastases since data acquisition was not synchronized to the cardiac cycle, in general provided suboptimal information. Three of five patients with metastases showed ECG changes and 12 of 14 patients without cardiac metastases. From this study we concluded that cardiac metastases of islet cell tumours are likely more frequent than reported in the literature until now. Increased awareness is necessary when evaluating patients with islet cell tumors for metastatic disease. If cardiac metastases are found serial ECG recordings during follow-up and the relation with changes might identify patients at risk for sudden cardiac death and allows timely initiation of treatment. The discovery of cardiac metastases may well have impact on the prognosis of 
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Summary an individual patient. In these patients cardiac metastases can best be identified with 11C-5-HTP PET. This issue is further addressed in chapter 4a, by describing a patient in whom two previously unknown cardiac metastases of a carcinoid tumor were found on 18F-DOPA PET, but missed on SRS and echocardiography. The ECG was normal, apart from a sinus bradycardia during metoprolol for hypertension. ECG-gated cardiac MRI confirmed the presence of cardiac metastases. This is another prove for raised awareness for cardiac metastases in a patient with a neuroendocrine, in this case with a carcinoid tumor. In chapter 5 we studied second primary malignancies in patients with carcinoid tumors, which are known to occur in up to 46% of these patients. These second primary malignancies can deserve full treatment, distinguishing a second primary malignancy from carcinoid lesions is important. Data were analyzed of 105 carcinoid patients seen at the Department of Medical Oncology for treatment and follow-up. We identified three patients who presented with a new second primary malignancy in whom differentiation between carcinoid lesions and the second primary malignancies was guided by functional imaging of the catecholamine pathway with 18F-DOPA PET and 18F-FDG PET as radiotracer for the glucose metabolism. All three patients had metastatic carcinoid disease and localized adenocarcinoma or planocellular carcinoma based on the PET scans. For their carcinomas they all received curative treatment. This study showed that the difference in uptake between 18F-FDG and 18F­DOP A in tumor lesions can be used to distinguish between second primary malignancies and metastases from the carcinoid tumor, without the need for invasive diagnostics. This can clearly have therapeutic consequences, allowing curative treatment for non-metastasised second primary malignancies, even in case of metastatic carcinoid disease. - 161 -
Chapter 9 Carcinoid tumors can produce and secrete a variety of biochemical markers, including serotonin and in up to 48% of patients also catecholamines. If metastatic carcinoid tumors show production of biochemical tumor markers in plasma or urine, then the measurement of these markers is used in the diagnosis and follow-up of these tumors. PET imaging opens ways to analyze a whole-body metabolic tumor burden, defined as uptake intensity x tumor volume, as a new quantitative measure of the overall tumor load. 18F-DOP A-tumor uptake is mediated by endocrine metabolic activity, just as the levels of tumor markers. In chapter 6 we therefore whether total 18F-DOPA -tumor uptake on PET, defined as the whole-body metabolic tumor burden is a measure of the tumor load per patient, as measured with tumor markers. Data of 76 patients with a carcinoid tumor who underwent 18F-DOPA PET as well as a careful collection of relevant biochemical tumor markers in two previously published 18F-DOPA PET studies of our institute were analyzed. The inclusion criteria for these studies were patients with a strong suspicion of a carcinoid tumor, based on clinical and biochemical findings, and patients with histopathologically proven carcinoid tumor, with a clinical indication for (re)staging. All patients had to have at least one abnormal lesion on conventional imaging. As tumor markers served 24-hour urinary serotonin, urine and plasma 5-hydroxindole acetic acid (SHIAA); catecholamines (nor)epinephrine, dopamine and their metabolites, measured in urine and plasma, and serum chromogranin A. The whole-body metabolic tumor burden correlated with urinary and plasma and markers of both the serotonin and catecholamine pathway. 18F­DOP A PET tumor uptake varied greatly between carcinoid lesions within individual patients, up to 29-fold differences between individual lesions were observed. In addition, there was also great inter-patient variance. The latter was caused by varying numbers of lesions between patients, but also by varying uptake intensities. - 162 -
Summary In conclusion, total tumor load per patient defined as whole-body metabolic tumor burden measured with 18F-DOP A PET correlates with metabolic tumor activity in carcinoid patients. It also gives a whole-body presentation of the specific sites where endocrine production is occurring. In future, whole-body metabolic burden may come to serve as alternative assessment parameter to evaluate disease extent and biochemical activity in carcinoid patients. 
Chapter 7 describes three patients with a metastasized insulinoma who were treated with the mammalian target of rapamycin (mTOR) inhibitor everolimus. A recent report described achievement of stunningly rapid control of hypoglycemias in four insulinoma patients upon everolimus treatment (Kulke et al. N Engl J Med 2009, 360, 195-197). The precise explanation for these findings is still unknown. We performed laboratory analyses and 18F-FDG PET imaging to identify the kinetics of everolimus-effects on control of hypoglycemias and understand underlying mechanisms. Everolimus normalized plasma glucose levels in all three patients within 14 days which coincided with a lower glucose uptake in tumor and muscles on 18F-FDG PET and decrease in (pro)insulin levels. This effect of everolimus on tumor as well as normal tissues is caused by decline in (pro )insulin excretion together with increased peripheral insulin resistance and explains the rapid control of hypoglycemias observed. In this study we demonstrated how imaging can help to understand and visualize the mechanism behind drug actions. In Chapter 8 we evaluated the frequency and severity of fat-soluble vitamin deficiencies in acromegaly and carcinoid patients, two groups that frequently receive long-term treatment with a somatostatin analogue. Somatostatin analogues negatively influence fat uptake in the bowel, frequently resulting in steatorrhea. Together with fat, potentially fat­soluble vitamins can be lost in the stool. In current standard practice vitamin status is not routinely assessed in these patients. The effect of long-- 163 -
Chapter 9 term use of somatostatin analogues on fat-soluble vitamin levels is unknown. Therefore we investigated the frequency and severity of fat­soluble vitamin deficiencies in long-term users. We evaluated symptoms of vitamin deficiency and measured levels of all four fat-soluble vitamins together with vitamin-dependent parameters in 19 patients with acromegaly and 35 carcinoid patients that were treated with a somatostatin analogue for longer than 18 months in a single centre cross-sectional study. Twelve patients experienced steatorrhea, two carcinoid patients had signs of night blindness. Forty-two patients (78%) had too low levels of one or more fat-soluble vitamins, 17 patients (32%) for multiple vitamins. Vitamin Kl was with 63% most frequently deficient, vitamin A in 6%, D in 28%, E in 15% and vitamin E in erythrocytes in 58%. Frequency or severity of vitamin deficiencies did not differ between patients with acromegaly or carcinoid for vitamin D, E and Kl. Duration of somatostatin analogue treatment did not influence vitamin levels. Length of intestinal resection and age were negatively correlated with vitamin A levels. Elevated parathyroid hormone was seen in 14 patients, lengthened prothrombin time in three. From these data we concluded that deficiencies of fat-soluble vitamins, including vitamin Kl and vitamin A, are more frequent in patients rece1vmg long-term somatostatin analogue treatment than previously reported. Therefore, fat-soluble vitamin status should be monitored and deficiencies supplemented, especially in patients with a previous intestinal resection. 
FUTURE PERSPECTIVES In this thesis we have addressed several aspects in the diagnosis and management of patients with neuroendocrine tumors. Neuroendocrine tumors are considered a rare disease according to the European definition - 164 -
Summary of rare diseases (i.e. a disease that affects less than 1 person per 2,000). We have shown how metabolic PET imaging can improve tumor localization in patients with catecholamine-producing tumors and detection of (unusual) metastases in patients with islet cell tumors. The specific ability of neuroendocrine tumors to take up and decarboxylate amine precursors, used by 18F-DOP A PET imaging, can help to non-invasively distinguish carcinoid metastases from second primary malignancies. Furthermore, this ability makes that tumor load on 18F-DOPA PET correlates with 5-HIAA, serotonin and the catecholamines in urinary measurements in carcinoid patients. All together, these results encourage further research to investigate the role metabolic PET imaging with 18F-DOPA and 11C-HTP can play in the diagnosis and management of patients with neuroendocrine tumors. In this chapter interesting future applications for which PET imaging with 18F-DOPA and 11C-HTP could be used will be briefly explored. 
18F-DOP A PET imaging for response assessment Currently, there is some debate about the optimal tumor marker for follow-up and management of patients with a carcinoid tumor Serum chromogranin A has been suggested as replacement of urinary 5-HIAA, as the collection of the latter can be unreliable and is inconvenient for the patient. Chromogranin A was shown to correlate with tumor load in patients with neuroendocrine tumors. Unlike 5-HIAA it does not does not reflect the metabolic tumor activity, as we have demonstrated in chapter 6. CT shows mainly stable disease in patients with neuroendocrine tumors, while biochemical response rates are much higher. These CT based response rates should be viewed with some caution when trying to predict treatment outcome of agents that induce mainly growth suppression but little actual tumor shrinkage in these indolent tumors. Lack of progression may be associated with a longer survival. Currently, functional information - 165 -
Chapter 9 of PET is already incorporated into staging and follow-up as surrogate response marker in Non-Hodgkin lymphoma. In the revised RECIST guidelines (18F-FDG) PET now serves to complement CT scanning in the assessment of progressive disease (especially for the detection of 'new' disease). It can also be used to establish a complete response in a manner similar to a biopsy in cases where a residual radiographic abnormality is thought to represent fibrosis or scarring In view of this the whole-body metabolic tumor burden may prove an interesting surrogate marker in carcinoid patients, since it has demonstrated a good correlation with the metabolic activity of the carcinoid tumor, as shown in chapter 6. The additional advantage is that it is a one-stop diagnostic modality where excellent tumor localization and information about the metabolic tumor activity are both obtained with one scan. The value of the whole-body metabolic tumor burden on 18F-DOP A PET should therefore be investigated as marker for the evaluation of treatment. 18F-DOP A PET scans performed before and after treatment, in addition to biochemical analyses are needed to elucidate the usefulness of this technique as a possible response marker. 
18F-DOPA and 11C-5-HTP PET imaging of cardiac metastases In recent years a number of case reports have appeared indicating that cardiac metastases from neuroendocrine tumors probably occur more frequently than reported in the past. PET scanning with 18F-DOP A and 11C-5-HTP PET has superior sensitivity compared to conventional imaging techniques in the detection of neuroendocrine tumors, due to its good spatial resolution and low cardiac background uptake. This offers the possibility to better detect cardiac metastases than in the past, as we have shown in chapter 4 and 4a. Detection of patients with cardiac metastases allows for closer monitoring of these patients, to prevent potentially dangerous arrhythmic episodes. A combination of better imaging techniques and raised awareness in all doctors involved is necessary to - 166 -
Summary change our understanding of the incidence of cardiac metastases from neuroendocrine tumors. No prospective studies have yet been performed to look at the incidence of cardiac metastases detected with 18F-DOP A PET and/or 11C-5-HTP PET. Future studies should prospectively investigate the value of metabolic PET tracers for the detection of cardiac metastases of neuroendocrine tumors, especially in patients with unexplained new ECG­abnormalities. Expanding metabolic PET imaging to other tumors 
18F-DOPA PET has now been tried for the imaging of most neuroendocrine tumors, with great success. Theoretically, 18F-DOP A PET should also be able to perform well in patients with neuroblastoma. These tumors arise from the sympathetic nervous system and are characterized by the fact that they can take up, store and secrete catecholamines. Currently, 1231-MIBG scintigraphy is recommended as the functional nuclear imaging technique of first choice for the staging of neuroblastomas. The excellent spatial resolution and good tumor-to-background ratio of PET, may give 18F-DOP A PET a better sensitivity in these tumors than 1231-MIBG scintigraphy, as it did in pheochromocytomas. 1231-MIBG scintigraphy can miss small lesions, especially in the liver and the brain, and also a considerable number of bone marrow relapses. In addition, up to 10% of neuroblastomas lack MIBG avidity. No studies have yet been performed to investigate the value of 18F-DOPA PET in neuroblastomas which is of interest to see whether it can improve initial localization and the timely detection of recurrences. Other PET tracers in neuroendocrine tumors Next to metabolic PET imaging, also other properties of neuroendocrine tumors can be imaged. This can include somatostatin - 167 
Chapter 9 receptors, as used with for example 68Ga-DOTA TOC en 68Ga-DOTA NOC. Another possible imaging target could be angiogenesis. Neuroendocrine tumors are highly vascularized, a result of profound angiogenesis. One of the best studied pro-angiogenic growth factors is the vascular endothelial growth factor (VEGF). In nude mice implanted with the human neuroendocrine tumor cell line BON-1 interferon-treatment induced reduction in VEGF expression, which was associated with reduction in microvessel density and tumor growth. Also, tumor VEGF expression patterns in 50 cases of resected human carcinoid tumors were found to correlate with metastases and decrease progression-free survival duration. These studies indicate that VEGF inhibition may be a useful therapeutic strategy in neuroendocrine tumors. Indeed, antiangiogenic drugs including sunitinib (which blocks the VEGF receptor), bevacizumab (a monoclonal antibody against VEGF) and the mTOR inhibitor everolimus have shown antitumor activity in neuroendocrine tumors. mTOR inhibitors block VEGF expression, angiogenesis and vascular permeability, but also achieve a direct antitumor effect. It is currently not possible to predict which individual patient will benefit from treatment with a mTOR inhibitor. A predictive biomarker for efficacy of mTOR inhibitors is urgently needed and would be helpful, as it may facilitate the development of combination therapies, of individual dose titration, may reduce costs and spare the patients unnecessary side effects. The aforementioned studies suggest that serial non-invasive VEGF quantification in tumor lesions may be an excellent predictive biomarker for efficacy of mTOR inhibitors. It would be interesting to investigate whether all neuroendocrine tumors produce VEGF and whether they differ in their response to inhibition of VEGF by mTOR inhibitors. A non-invasive way to achieve this is by using in vivo VEGF imaging with Zirconium-89 (89Zr) bevacizumab PET, which binds to all VEGF-A splice variants. -168 -
Summary 
Patient management in centers of reference Finally, given the rarity of neuroendocrine tumors relevant knowledge and expertise are scarce. Misdiagnosis, non-diagnosis and lack of knowledge about treatment options are the main hurdles to improving life quality. Given the increasing options for diagnosis and treatment of patients with neuroendocrine tumors they should be referred to centres with specific expertise in this field. Concentrating management of these patients in centres with technical resources, a multidisciplinary team when necessary and clinical research expertise is important to ensure an optimal approach and facilitate meaningful research. In addition, creating large enough cohorts that are followed for a long time will enable us to gain insight in late adverse treatment effects of these rare tumors. - 169 -

Chapter 10 N ederlandse samenvatting 
Chapter 10 Neuroendocriene tumoren zijn een heterogene groep, zeldzaam voorkomende tumoren. De incidentie van deze tumoren is ongeveer 10 tot 20 nieuwe gevallen per miljoen mensen per jaar. Deze neuroendocrine tumoren ontstaan uit cellen van het neuroendocriene systeem. Deze cellen bevinden zich in het hele lichaam en kunnen hormonen produceren. Ze warden onderverdeeld in cellen die gelokaliseerd zijn in klieren (bijv. in het bijniermerg en de paraganglia) en cellen die verspreid zijn in andere organen door het hele lichaam: het diffuse neuroendocriene systeem. Tumoren die uitgaan van de chromaffine-houdende cellen van het bijniermerg warden geclassificeerd als feochromocytomen, terwijl tumoren uitgaand van de sympathische en parasympathische paraganglia paragangliomen genoemd warden. N euroendocriene tumoren van het diffuse neuroendocriene systeem bevinden zich voornamelijk in de darmen, de pancreas en de longen. Ze kunnen echter ook in andere organen ontstaan. Intestinale neuroendocriene tumoren bevinden zich meestal in de dunne darm, gevolgd door het rectum en de appendix. Neuroendocriene tumoren in de pancreas warden eilandjesceltumoren genoemd. Het classificatiesysteem van de wereldgezondheidsorganisatie (WHO) deelt neuroendocriene tumoren in op basis van histologische eigenschappen. De hoofdcategorieen, op basis van dit classificatiesysteem, zijn goed gedifferentieerde neuroendocriene tumoren, goed gedifferentieerde neuroendocriene tumoren met onzeker gedrag, goed gedifferentieerde neuroendocriene carcinomen en slecht gedifferentieerde neuroendocriene carcinomen. In dit proefschrift wordt de naam carcino:id gebruikt voor goed gedifferentieerde intestinale neuroendocriene tumoren. Om de primaire tumor te lokaliseren bij een patient die verdacht wordt van een neuroendocriene tumor wordt anatomische beeldvorming, zoals computer tomografie (CT), magnetic resonance imaging (MRI) of endoscopische echografie. Functionele nucleaire beeldvorming wordt eveneens toegepast bij het opsporen van de primaire tumor en wordt - 172 
Nederlandse samenvatting gebruikt om eventuele uitzaaiingen opsporen die buiten het bereik van de gekozen anatomische beeldvorming liggen. Voorbeelden van nucleaire technieken zijn somatostatinereceptorscintigrafie (SRS) met 111ln-octreotide (voor carcino:idtumoren en eilandjesceltumoren) of scintigrafie met 1231-gelabeled meta-iodobenzylguanidine (voor feochromocytomen). Positronemissietomografie (PET) met de catecholamine-voorloper 6-[F-18]fluoro-L-dihydroxyphenylalanine (18F-DOPA) of de serotonine­voorloper 11C-5-hydroxytryptophan (11C-5-HTP) is gebaseerd op het feit <lat neuroendocriene tumoren deze specifieke amine-voorlopers kunnen opnemen, decarboxyleren en opslaan. Deze technieken zijn veel gevoeliger dan conventionele beeldvormende technieken bij patienten met neuroendocriene tumoren. Er is nog geen goed overzicht van de relatieve waarde van alle op dit moment beschikbare beeldvormende technieken, in het bijzondere voor eilandjesceltumoren. Dit wordt mede veroorzaakt door het feit dat <lit zeldzame tumoren zijn en veel nieuwe technieken nog maar kortdurend en beperkt beschikbaar zijn. Daar komt bij dat in de gepubliceerde onderzoeken de indicaties voor het inzetten van beeldvorming varieren, directe een-op-een vergelijkingen zijn zeldzaam en de meeste studies zijn gedaan met kleine patientenaantallen. Chirurgische resectie is de enige curatieve behandelingsoptie. Chirurgie kan echter ook toegepast worden in de palliatieve fase om lokale problemen te voorkomen of om de hormoonproductie te verminderen. Zelfs in geval van gemetastaseerde ziekte is de mediane overleving van goed gedifferentieerde neuroendocriene tumoren relatief lang. Het doel van <lit proefschrift is om het diagnosticeren en de behandeling van patienten met neuroendocriene tumoren te onderzoeken, in het bijzondere van carcino:idtumoren, eilandjesceltumoren en feochromocytomen. In hoofdstuk 2 geven we een overzicht van de literatuur op het gebied van anatomische en functionele nucleaire technieken voor het lokaliseren van eilandjesceltumoren. De PubMed, Medline en Embase - 173 -
Chapter 10 databases zijn doorzocht naar alle Engelstalige publicaties over beeldvorming van in de pancreas gelokaliseerde eilandjesceltumoren tussen 1995 en januari 2010 . Indien meer dan vijf studies beschikbaar waren over een bepaalde beeldvormende techniek, zijn alleen de studies met meer dan 10 patienten in de analyse meegenomen. Wij hebben drie indicaties onderscheiden voor het toepassen van beeldvorming, namelijk 1) tumor lokalisatie en stadiering van een patient met symptomatische hormoonhypersecretie, 2) een toevallig ontdekte neuroendocriene tumor of metastasen daarvan en de daaropvolgende opsporing van een primair (pancreas)tumor en 3) screening van asymptomatische VHL en MENl­mutatiedragers. Resultaten van de klinische toepassing van de verschillende beeldvormende technieken werden per indicatie en per tumortype besproken. Met Forest plots werd de sensitiviteit van de verschillende beeldvormende technieken weergegeven. Voor de toepassing van elke beeldvormende techniek werd een 'level of evidence' toegekend. De 'level of evidence' voor alle indicaties en beeldvormende technieken was opmerkelijk laag (maximaal 2b). Voor patienten met een bij toeval ontdekte neuroendocriene tumor kon er geen aparte sensitiviteit berekend warden, aangezien de patienten in studies altijd samen geanalyseerd werden met symptomatische patienten. De patientenaantallen in de meeste studies waren klein. Bij symptomatische patienten en patienten met een bij toeval gevonden tumor heeft anatomische beeldvorming door middel van echografie, CT, MRI een matige sensitiviteit, hoewel technische ontwikkelingen de sensitiviteit zouden kunnen verbeteren. Endoscopische echografie en nieuwe metabole PET technieken laten betere resultaten zien. Slechts weinig studies hebben de waarde van beeldvormende technieken voor screening van mutatiedragers onderzocht. De beste resultaten zijn behaald met endoscopische echografie, terwijl CT en SRS een matige sensitiviteit laten zien. Echografie, MRI en PET zijn niet onderzocht in deze patientenpopulatie. 
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Nederlandse samenvatting In hoofdstuk 3 onderzoeken we de sensitiviteit van 18F-DOP A PET bij patienten met een verhoogde catecholamine productie. Tot op heden includeerden de meeste studies patienten op basis van ( de verdenking van) een feochromocytoom of paraganglioom. In deze studie bekijken we deze kwestie vanuit de klinische situatie, waarin de patienten zich presenteren met een catecholamine overproductie. De standaard beeldvormende diagnostiek bij deze patienten bestaan uit CT of MRI, meestal in combinatie met 123I-MIBG scintigrafie. Als de lokalisatie van de primaire tumor bekend is, is het belangrijk om metastasen uit te sluiten, aangezien het vaststellen hiervan de behandeling sterk kan bepalen. Gebaseerd op de initiele resultaten van kleinere studies lijkt 18F-DOP A PET de potentie te hebben om de tumor en eventuele metastasen beter te lokaliseren en dus ook stadiering te kunnen verbeteren. In deze studie hebben we daarom 18F­DOP A PET vergeleken met de conventionele beeldvormende technieken CT of MRI en 123I-MIBG scintigrafie. In totaal werden 48 patienten geanalyseerd. De analyse werd uitgevoerd op patient- en tumorlaesie-niveau. Resultaten van de combinatie van cytologie, histologie, alle beeldvormende technieken, follow-up en biochemie dienden als samengestelde gouden standaard. Metanefrines en 3-methoxytyramine werden bepaald in plasma en urine. Opname van 18F­DOP A in de laesies werd gemeten met PET om de 'totale lichaam metabole tumor last' te bepalen en deze te correleren aan biochemische tumormerkstoffen. 
18F-DOPA PET liet tumorhaarden zien in 43 patienten, 123I-MIBG in 31 en CT /MRI in 32 patienten. Uiteindelijk werden de volgende diagnoses gesteld: feochromocytoom in 40, bijnierhyperplasie in twee, paraganglioom in twee, ganglioneuroom in een. De diagnose bleef onbekend in drie. Sensitiviteit op patientniveau voor 18F-DOPA PET, 123I-MIBG en CT/MRI was respectievelijk 90, 65 en 67% (P < 0.01 voor 18F-DOP A PET versus zowel 123I-MIBG als CT/MRI en P = 1.0 123I-MIBG versus CT/MRI). Sensitiviteit op laesieniveau was respectievelijk 73, 48 en 44% (P < 0.01 voor - 175 -
Chapter 10 
18F-DOPA PET versus zowel 123I-MIBG als CT/MRI en P = 0.51 123I-MIBG versus CT/MRI). De combinatie van 18F-DOPA PET en CT/MRI was superieur aan de combinatie van 123I-MIBG en CT/MRI (93 versus 76%, P < 0.001). De 'totale lichaam metabole tumor last' gemeten met 18F-DOPA PET correleerde met plasma vrije normetanefrine (r = 0.82), en urine normetanefrine (r = 0.84) en metanefrine (r = 0.57). Uit de resultaten van deze studie concluderen we dat 18F-DOP A PET beter in staat is tumoren te lokaliseren bij patienten met een catecholamine overproductie dan 123I-MIBG scintigrafie en CT/MRI. Additionele informatie verkregen met de 18F-DOP A PET scan heeft een verbeterde stadiering en een verandering van het behandelplan bij 14 patienten (29%) tot gevolg. De combinatie van 18F-DOPA PET en CT/MRI levert de meeste informatie op voor het diagnostische traject van deze patienten. Deze combinatie heeft als extra voordeel dat CT en MRI anatomische lokalisatie leveren voor de laesies die gezien warden op 18F-DOPA PET. In hoofdstuk 4 bestuderen we de waarde van 1 1C-5-HTP PET om cardiale metastasen in patienten met een gemetastaseerde eilandjesceltumor te ontdekken. Door bij toeval gevonden cardiale metastasen in een patient met een eilandjesceltumor werden we geattendeerd op het feit dat deze metastasen mogelijk frequenter voorkomen dan verondersteld. 11C-5-HTP PET is op het moment de meest gevoelige beeldvormende techniek om eilandjesceltumoren zichtbaar te maken. Daarom besloten we alle 11C-5-HTP PET scans van patienten met een gemetastaseerde eilandjesceltumor opnieuw te analyseren, met speciale aandacht voor myocardiale metastasen. Uit een database van alle 11C-5-HTP PET scans die uitgevoerd zijn in het Universitair Medisch Centrum Groningen werden alle patienten met een gemetastaseerde eilandjesceltumor ge'identificeerd die een 11C-5-HTP PET scan ondergingen. Een groep van 26 patienten was beschikbaar voor verdere analyse. Vijf patienten (19%) hadden een of meer voor cardiale metastasen verdachte laesies op 1 1 C-5-HTP PET. Geen enkele patient had - 176 -
Nederlandse samenvatting klinische tekenen of klachten passend bij cardiale dysfunctie. Bij een patient was de cardiale laesie na fusie met 11C-5-HTP PET ook zichtbaar op CT. Gezien het feit dat de beschikbare thorax-CT scans niet gemaakt waren met de intentie om cardiale metastasen aan te tonen en dus niet gesynchroniseerd waren met het hartritme, leverden deze over het algemeen suboptimale informatie. Drie van de vijf patienten met cardiale metastasen lieten ECG-veranderingen zien, net als 12 van de 14 patienten zonder cardiale metastasen bij wie een ECG beschikbaar was. Uit deze studie concluderen we dat cardiale metastasen van eilandjesceltumoren waarschijnlijk vaker voorkomen dan tot nu toe in de literatuur beschreven wordt. Kennis en aandacht voor het voorkomen van cardiale metastasen is van belang bij de evaluatie van patienten met een eilandjesceltumor om de uitgebreidheid van de gemetastaseerde ziekte vast te stellen. In hoofdstuk 4a beschrijven we een patient met cardiale metastasen van een carcinoi:dtumor. Bij deze patient werden twee van tevoren onbekende cardiale metastasen van een carcinoi:dtumor ontdekt op de 18F­DOP A PET scan, die niet gezien werden op SRS en met echocardiografie. Afgezien van een sinusbradycardie, onder metoprolol gebruik voor hypertensie, was het ECG normaal. Een ECG-gesynchroniseerde cardiale MRI bevestigde de aanwezigheid van cardiale metastasen. Deze patient illustreert dat cardiale metastasen ook voor kunnen komen bij patienten met een carcinoi:dtumor. Hiermee wordt nog eens extra benadrukt dat cardiale metastasen waarschijnlijk frequenter voorkomen bij patienten met neuroendocriene tumoren en dat hier bewust aan gedacht moet worden. In hoofdstuk 5 bestuderen we tweede primaire niet-carcinoi:de maligniteiten bij patienten met een carcinoi:dtumor. Deze worden gezien bij tot wel 46% van deze patienten. Gezien de lange overleving van patienten met een carcinoi:dtumor kan behandeling van een tweede niet-carcinoi:de primaire maligniteit gerechtvaardigd zijn. Daarom is het van belang om onderscheid te maken tussen een tweede primaire maligniteit en - 177 
Chapter 10 metastasen van de carcinoi:dtumor. Het verschil in opname tussen 18F­DOP A, als tracer van de catecholamine pathway welke uitstekend opgenomen wordt door carcinoi:dtumoren, en 18F-FDG als tracer voor het glucose metabolisme, die door vele niet-carcinoi:de maligniteiten goed opgenomen wordt, kan gebruikt worden bij het onderscheid tussen tweede primaire niet-carcinoi:de maligniteiten en carcinoi:d metastasen. De therapeutische consequenties van het in kaart brengen van de uitbreiding van de tweede primaire niet-carcinoi:de maligniteit is om het nut van eventuele curatieve resectie bij een reeds gemetastaseerde carcinoi:dtumor te bepalen. Data van 10 5 patienten met een carcinoi:dtumor, die gezien werden op de Afdeling Medische Oncologie van het UMCG voor behandeling en follow­up, werden geanalyseerd om carcinoi:dpatienten te identificeren, die tijdens de onderzoeksperiode een primair adeno- of plaveiselcelcarcinoom ontwikkeld hadden en bij wie differentiatie tussen carcinoi:dlaesies en adeno- of plaveiselcelcarcinoom essentieel was voor het al dan niet instellen van een curatieve behandeling van het carcinoom. We konden drie carcinoi:dpatienten identificeren bij wie deze differentiatie werd gefaciliteerd door functionele beeldvorming middels 18F-DOP A PET en 18F­FDG PET. Alle drie patienten hadden een gemetastaseerde carcinoi:dtumor en een gelokaliseerd adenocarcinoom of plaveiselcelcarcinoom op basis van hun PET scans. De niet-carcindide maligniteit kon curatief behandeld worden in alle patienten. Deze studie laat zien dat het verschil in opname tussen 18F-DOP A en 18F­FDG door tumor laesies inderdaad gebruikt kan worden om op niet­invasieve manier bepaalde tweede primaire maligniteiten en carcinoi:d metastasen van elkaar te onderscheiden. Carcinoi:d tumoren kunnen een verscheidenheid aan biochemische tumormerkstoffen, zoals serotonine en catecholamines, produceren en secerneren. Deze kunnen gebruikt warden voor het diagnosticeren en de follow-up van de carcinoi:dtumor. Met behulp van een PET scan kan op 
- 178 
Nederlandse samenvatting een and ere manier een 'totale lichaam meta bole tumorlast' bepaald worden als een nieuwe kwantitatieve maat voor de totale hoeveelheid tumor. Deze wordt gedefinieerd als intensiteit van de opname x tumor volume. 18F­DOP A tumoropname wordt bepaald door de endocriene metabole activiteit van de tumor, net als het niveau van de tumormerkstoffen. In hoofdstuk 6 onderzoeken we of de totale 18F-DOP A-opname op de PET scan, gedefinieerd als de 'totale lichaam metabole tumorlast' een maat is voor de hoeveelheid tumor, zoals deze bepaald wordt met biochemische tumormerkstoffen. Gegevens van 76 patienten met een carcino:idtumor, die een 18F-DOPA PET hadden gehad in twee eerder door ans instituut gepubliceerde 18F-DOP A PET-studies en van wie eveneens biochemische tumormerkstoffen bekend waren werden geanalyseerd. Patienten werden ge:includeerd in deze voorgaande studies als er een sterke verdenking bestond op een gemetastaseerde carcino:idtumor, gebaseerd op kliniek en biochemie, of als ze een histologisch bewezen carcino:idtumor hadden en er een klinische indicatie voor (her)stadiering was. Alle patienten moesten minimaal een abnormale laesie hebben op conventionele beeldvorming. Als tumormerkstoffen dienden 24-uurs urine serotonine, urine en plasma 5-hydroxyindool azijnzuur (SHIAA), de catecholamines (nor)adrenaline, dopamine en hun metabolieten gemeten in urine en plasma en serum chromogranine A. De 'totale lichaam metabole tumor last' correleerde met tumormerkstoffen uit zowel de serotonine als de catecholamine pathway gemeten in urine en plasma. 18F-DOPA PET-opname liet tot wel 29-voudige verschillen zien tussen verschillende carcino:idlaesies binnen een patient. Tevens was er sprake van een grate variatie tussen de patienten. Dit laatste werd veroorzaakt door verschillende aantallen laesies, maar oak door verschillende opname-intensiteiten. Uit deze analyse kan warden geconcludeerd dat de totale tumorlast gedefinieerd als 'totale lichaam metabole tumorlast' gemeten met 18F­DOP A PET correleert met metabole tumor activiteit in de gemetastaseerde - 179 -
Chapter 10 carcinoi:dpatient. Daarnaast geeft het in het gehele lichaam een overzicht over de plaatsen waar endocriene productie plaatsvindt. In toekomst zou de 'totale lichaam metabole tumor last' gebruikt kunnen warden als alternatieve parameter om uitgebreidheid en biochemische activiteit van carcinoi:dtumoren te evalueren. In Hoofdstuk 7 beschrijven we drie patienten met een gemetastaseerd insulinoom die behandeld werden met de mammalian target of rapamycin (mTOR) remmer everolimus. Een recent artikel heeft laten zien dat everolimus verbazingwekkend snelle controle van hypoglycemieen bewerkstelligde in vier patienten met een insulinoom (Kulke et al. N Engl J Med 2009, 360, 195-197). Het precieze werkingsmechanisme is nog niet bekend. Om bij onze patienten hierin meer inzicht te krijgen voerden we laboratoriumanalyses en 18F-FDG PET uit om de kinetiek van de everolimus effecten op de glycemische controle en <liens onderliggende mechanismen te onderzoeken. Everolimus normaliseerde de plasma glucosespiegels in alle drie patienten binnen 14 dagen. Dit viel samen met een lagere glucoseopname in de tumor en spieren op 18F-FDG PET en een daling van de (pro)insulinespiegels. Het effect van everolimus op zowel tumor als op normale weefsels werd veroorzaakt door gedaalde (pro)insuline uitscheiding in combinatie met perifere insulineresistentie en verklaarde de snelle glucosecontrole. In deze studie laten we zien hoe beeldvorming kan helpen om het werkingsmechanisme van geneesmiddelen te begrijpen en te visualiseren. In hoofdstuk 8 evalueren we de frequentie en de ernst van het gebrek aan vetoplosbare vitamines in acromegalie- en carcinoi:dpatienten. Beide patientengroepen warden vaak langdurig behandeld met een somatostatine-analoog. Somatostatine-analogen hebben een negatieve invloed op de vetopname in de darmen, waardoor er vaak steatorrhoe ontstaat. Samen met het vet kunnen mogelijk ook de vetoplosbare vitamines verloren gaan. De vetoplosbare vitamines warden niet routinematig gecontroleerd bij deze patienten. Het effect van langdurige - 180 -
Nederlandse samenvatting behandeling met somatostatine-analogen op vetoplosbare vitaminespiegels is nog onbekend. Daarom onderzochten wij de frequentie en de ernst van het gebrek aan vetoplosbare vitamines. In een cross-sectionele studie evalueerden we symptomen van een mogelijke deficientie van vetoplosbare vitamines bij 19 acromegalie­patienten en 35 carcino1dpatienten die langer dan 18 maanden behandeld waren met een somatostatine-analoog. Tevens bepaalden we de spiegels van de vier vetoplosbare vitamines (A, D, E en Kl) en vitamine­afhankelijke parameters (parathormoon voor vitamine D, prothrombine en geactiveerde partiele thromboplastine tijd voor vitamine Kl). Twaalf patienten hadden last van steatorrhoe, twee carcino1dpatienten klaagden over nachtblindheid. Tweeenveertig patienten (78%) had den te lage spiegels van een of meer vetoplosbare vitamines, 17 patienten (32%) hadden een verlaagde spiegel van meerdere vitamines. Vitamine Kl was het meest frequent verlaagd (in 63%), vitamine A was verlaagd in 6%, D in 28%, E in 15% en vitamine E gemeten in erythrocyten in 58%. Frequentie en ernst van deficienties in vitamine D, E en Kl waren niet verschillend tussen acromegalie- en carcino1dpatienten. De behandelduur met de somatostatine-analoog had geen invloed op de vitaminespiegels. Lengte van de darmresectie en leeftijd correleerden negatief met vitamine A spiegels. Een verhoogd parathormoon werd gezien in 14 patienten en een verlengde prothrombine tijd in drie patienten. Uit deze gegevens concluderen wij dat een tekort aan vetoplosbare vitamines, waaronder vitamine Kl en vitamine A, vaker voorkomen in patienten die behandeld warden met een somatostatine analoog dan voorheen gedacht. Daarom zouden de spiegels van deze vetoplosbare vitamines gecontroleerd en zo nodig gesuppleerd moeten warden, in ieder geval bij patienten die in het verleden een darmresectie ondergingen. Samenvattend, door middel van PET met 18F-DOPA en 11C-5-HTP is een betere detectie van neuroendocriene tumorlaesies mogelijk ten opzichte van conventionele beeldvorming en deze technieken zijn daardoor - 181 -













transporter Figure 6. Schematic depiction of the different metabolic pathways by which neuroendocrine tumors can be visualized using nuclear medicine imaging techniques. This can be receptor based techniques and techniques which use the metabolic properties of these tumors. 1 1C-5-HTTP: 11C-5-hydroxytryptophan, 18F­DOPA: 18F-fluoro-dihydroxyphenylalanin, 18F-FDG: 18F-fluoro-2-deoxy-d-glucose, 18F-FDG-6-P: 18F-fluoro-2-deoxy-d-glucose-6-phosphate, GLP-1:  glucagon-like peptide 1, LAT: large amino acid transporter, VMAT: vesicular monoamine transporter - 184 
Color figures Chapter 3 
A 
B Figure 2. Imaging of a patient with a known metastatic pheochromocytoma. (A) 18F-DOPA PET shows increased uptake in the left adrenal gland and three lesions in the spine (arrows). (B) Fusion image of 18F-DOPA PET and CT shows uptake in the region of the left adrenal gland, without anatomical substrate. (C) CT image of the region of the left adrenal gland. 123I-MIBG imaging was negative (not shown). 
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Appendix 
A B C D 
• • Figure 3. Patient with bilateral pheochromocytoma. (A) 18F-DOP A PET shows increased uptake in both adrenal glands. (B) 1231-MIBG imaging: asymmetric 1231 uptake in the adrenals: the left adrenal shows markedly increased uptake, whereas uptake in the right adrenal can easily be mistaken as physiological. (C) Fusion of 18F-DOP A PET and MRI shows uptake in both adrenal glands. (D) MRI showing the left adrenal pheochromocytoma. 
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Color figures Chapter 4 
A B Figure 1. Patient 3 A. 11C-5-HTP PET scan showing two cardiac metastases 
(arrows), both confirmed by CT scan, and extensive liver metastases. Diffuse 
physiological uptake in the pancreas and excretion via the kidneys, ureters and 
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Chapter 11 Onderzoek naar neuroendocriene tumoren wordt gedaan op het grensvlak van meerdere specialismen. Ik ben dan oak zeer blij <lat ik tijdens mijn promotie van verschillende kanten hulp en begeleiding gehad hebt. Dit was altijd gezellig, soms frustrerend en leverde vele leerzame en vermakelijke discussies op. Prof. dr. E.G.E. de Vries, Liesbeth, jouw scherpe blik en kritische opmerkingen hielpen menig probleem en onduidelijkheid oplossen. Het is ongelooflijk hoe snel je documenten van treffende opmerkingen kan voorzien, zodat ik vaak de volgende <lag alweer verder kon werken. Samen poli doen op vrijdag was een mooie afwisseling van het onderzoek doen. Ik ben blij <lat ik op deze manier toch met een been in de kliniek heb kunnen blijven staan. Prof. dr. T.P. Links, Thera, samen hebben we veel gefilosofeerd met een kopje thee op jouw kamer. Al pratende kwamen er zo vaak nieuwe inzichten om weer verder te kunnen. Oak als het even niet mee leek te zitten had je altijd opmonterende woorden. Prof. dr. LP. Kema, Ida, de biochemie was vaak het lastigste punt van mijn voornamelijk klinisch georienteerde onderzoek. Dan was ik altijd blij als jij tijd had om met jouw kennis naar de data te kijken en zo nieuwe inzichten te verkrijgen. Vaak leverde dat trouwens net zoveel nieuwe ( onderzoeks )vragen op als waarmee ik bij je kwam. Dr. A.H. Brouwers, Adrienne, bij jou kon ik altijd laagdrempelig aankloppen voor kleine alledaagse vragen en praktische problemen. Op het eind even vanaf de achtergrond om tijd te hebben voor je eigen wonder. -192 
Dankwoord Mijn kamergenoten, jullie waren er voor een kop latte met iets lekkers, als er weer een artikel geaccepteerd was, en om alle meevallers en tegenslagen mee te delen. Hartelijk dank voor alle gezelligheid! Corina en Renske, mijn paranimfen. Jullie waren er vanaf het begin bij en samen hebben we dit pad bewandeld. Hopelijk staan jullie hier binnenkort ook! Beste co-auteurs, hartelijk dank voor het bijdragen van jullie specifieke kennis om zo ons onderzoek steeds weer te kunnen verbeteren. Speciale dank in dit kader aan prof. dr. R.A.J.O. Dierckx, dr. J.R. de Jong, en dr. KP. Koopmans. Beste Rudi, hartelijke dank voor alle steun en alle mogelijkheden die ik gekregen heb om onderzoek te doen op de afdeling Nucleaire Geneeskunde en Moleculaire Beeldvorming (NGMB). Johan, dank je dat je altijd tijd had om moeilijke en 'suvve' concepten opnieuw uit te leggen. Klaas Pieter, dankzij jouw hulp hoefde ik aan het begin niet steeds het wiel opnieuw te ontdekken, dank je. Dank aan de velen op de afdeling NGMB die me steeds weer geholpen hebben met (technische) vragen. Een speciale dank ook aan de medisch nucleair werkers voor het "terugzetten" van ontelbare scans. Dear colleagues from the Department of Nuclear Medicicine and Molecular Imaging. It was always fun to talk to you over coffee during the coffee break, eat fish on the market or have a drink after work. Thom, hartelijk dank voor het maken van de mooie plaatjes en de lay-out! Zonder jouw hulp zou dit proefschrift er een stuk minder mooi en kleurrijk uitzien. Monique, hartelijk dank voor je redactie en voor de geestelijke en lichamelijke ontspanning en afleiding die onze vele gezellige (sport)avonden brachten. Ik zal ze gaan missen! - 193 
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